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The aims of the present article are to systematically review and meta-analyze the 
existing evidence on: 1) differences in physical activity (PA), sedentary behavior (SB), 
cardiorespiratory fitness (CRF) and muscular strength (MST) between metabolically 
healthy obesity (MHO) and metabolically unhealthy obesity (MUO); and 2) the 
prognosis of all-cause mortality and cardiovascular disease (CVD) mortality/morbidity 
in MHO individuals, compared with the best scenario possible, i.e., metabolically 
healthy normal-weight (MHNW), after adjusting for PA, SB, CRF or MST. Our 
systematic review identified 67 cross-sectional studies to address aim 1, and 11 
longitudinal studies to address aim 2. The major findings and conclusions from the 
current meta-analysis are: 1) MHO individuals are more active, spend less time in SB, 
and have a higher level of CRF (yet no differences in MST) than MUO individuals, 
suggesting that their healthier metabolic profile could be at least partially due to these 
healthier lifestyle factors and attributes. 2) The meta-analysis of cohort studies which 
accounted for PA (N=10 unique cohorts, 100% scored as high-quality) support the 
notion that MHO individuals have a 24-33% higher risk of all-cause mortality and CVD 
mortality/morbidity compared to MHNW individuals. This risk was borderline 
significant/non-significant, independent of the length of the follow-up and lower than 
that reported in previous meta-analyses in this topic including all type of studies, which 
could be indicating a modest reduction in the risk estimates as a consequence of 
accounting for PA. 3) Only one study has examined the role of CRF in the prognosis of 
MHO individuals. This study suggests that the differences in the risk of all-cause 
mortality and CVD mortality/morbidity between MHO and MHNW are largely 
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Obesity has increased markedly over the last several decades in most developed and 
developing countries (1-3), and it is clear today that obesity is a pathological condition 
associated with higher risk of suffering a myriad of physical, psychological and social 
problems. Among these problems are the metabolic alterations, which are clearly more 
frequent in obese than in normal-weight individuals (4). However, nearly 2 decades ago 
the existence of a subset of individuals that, despite being obese, had otherwise a 
healthy metabolic profile (5,6), and this was later named as the metabolically healthy 
obesity (MHO) phenotype. The concept of MHO refers to those individuals who are 
obese but do not have dyslipidemia, hyperglycemia/type 2 diabetes mellitus (T2DM), or 
hypertension (HTN). A recent meta-analysis has reported that one in every three (more 
precisely 35%) individuals with obesity is MHO (7), yet this percentage might change 
depending on the definition of MHO used, as previously discussed elsewhere (8). 
Although several specific definitions of MHO have been used in the literature, there 
seems to be more and more consensus that MHO should be defined as being obese 
according to the standard definition of a body mass index (BMI) equal or higher than 
30kg/m2 and having 0 of the metabolic syndrome (MetS) criteria (waist circumference -
WC-, excluded). More details about the proposed harmonized definition of MHO and 
the scientific base for it is provided in the original publication (see Table 2 and 3 in 
Ortega et al. (8)). The opposite condition among obese individuals is most commonly 
named as metabolically unhealthy obesity (MUO) and defined as an obese individual 
who meets at least 1 of the 4 MetS criteria (WC excluded). Both, MHO and MUO are 
often compared regarding prognosis and metabolic characteristics to the normal 




From the landmark studies of Drs. Morris, Paffenbarger and Blair (9-12) to date, vast, 
consistent and accumulating evidence supports the health benefits of high levels of 
physical activity (PA), low levels of sedentarism (i.e., sedentary behaviors, SB) and 
high levels of cardiorespiratory fitness (CRF) and more recently also muscular strength 
(MST) (13-24). However, to the best of our knowledge, the specific role of PA, SB, 
CRF and MST in the characterization and prognosis of the MHO has not yet been 
systematically reviewed and meta-analyzed.  
Over the last several years, the amount of studies focused on the MHO intriguing 
phenotype has been overwhelming. Figure 1 shows the number of articles published in 
PubMed about the MHO concept since it was first described in 2001. Some of these 
studies have addressed two key questions: 1) What are the characteristics of the MHO 
individuals? and 2) How is the prognosis of the MHO individuals compared with MUO 
and MHNW individuals? Concerning the first question, the early reviews on this topic 
did not consider a higher level of PA and/or CRF as a characteristic of the MHO when 
compared with MUO (25), except more recent ones (26), given recent evidence 
supporting this notion (27-33). However, to the best of our knowledge, the differences 
in PA and/or CRF between MHO and MUO have not been systematically reviewed and 
quantified using meta-analysis methods. Similarly, whether there are systematic 
differences between MHO and MUO in time spent in SB, and in other components of 
physical fitness, such as MST, is also currently unknown. 
Concerning the prognosis of MHO, a number of systematic reviews and meta-analyses 
have examined the risk of fatal and non-fatal cardiovascular disease (CVD), as well as 
all-cause mortality in MHO compared to MUO and MHNW (34-39). In addition to 
these systematic reviews and meta-analyses, some powerful studies have recently been 
published on this topic, such as The Health Improvement Network (THIN) cohort in 3.5 
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million participants (40), and the Nurses’ Health Study (NHS) in 90,257 women 
(32,41). Although controversy about this topic has existed in the near past, we believe 
that the current evidence coming from the systematic reviews/meta-analyses and the 
latest and more powerful original research studies mentioned above, clearly supports 
that there is no benign obesity. Thus, MHO individuals, even they have a markedly 
lower risk of future disease and death than MUO individuals, they still have a higher 
risk of mortality and morbidity than MHNW individuals (32). However, it is of utmost 
importance to note that most of the existing cohorts lack information about probably 
one of the most powerful predictors, and therefore potential confounder, of current and 
future metabolic health, all-cause mortality and CVD risk; that is CRF (24,28,30-33). 
Moreover, few studies have accounted for PA in their analyses, which is closely related 
to CRF, although always less objectively and accurately measured (42). Therefore, there 
is a gap in the current knowledge about the prognosis of MHO individuals, whether or 
not the higher risk reported in MHO, compared to MHNW, in most of existing studies, 
is explained by differences in CRF or PA. To the best of our knowledge, the role of 
CRF and/or PA in the prognosis of the MHO has not yet been systematically reviewed 
and meta-analyzed. 
Thus, the aims of the present article are to systematically review and meta-analyze the 
existing evidence on: 1) differences in PA, SB, CRF and MST between MHO and 
MUO; and 2) the prognosis of future all-cause and CVD mortality and morbidity (i.e., 
non-fatal CVD events) in MHO individuals, compared with the best scenario possible, 





Protocol and Registration 
The present systematic review and meta-analysis was conducted following the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement (43). 
The study protocol was registered in the International Prospective Register of 
Systematic Reviews (PROSPERO reference number: CRD42018093955). 
Data Sources and Search Strategies 
The search was conducted for studies published from inception to March 21, 2018 in two 
major electronic databases: PubMed and Web of Science. The keywords used in search 
strategy were related to the following topics: PA (motor activity, exercise, etc.), physical 
fitness (CRF, functional capacity, etc.), metabolic phenotypes (metabolically benign, 
metabolically healthy, etc.) and weight status (overweight and obesity). The connectors 
‘OR’ and ‘AND’ were used to combine the search terms. Specifically, for PubMed search, 
we used Medical Subject Heading (MeSH) terms combined with the tag for searching in 
title, abstract and keywords. As an example, for CRF we introduced: ("cardiorespiratory 
fitness” [Title/Abstract] OR cardiorespiratory fitness [MeSH]). Search terms and search 
strategies were adapted to each database (for more information, see Supplemental 
Material, Table S1). Additionally, the reference lists of retrieved studies were examined 
for identifying potential interesting articles.   
Once the search strategies for both databases were executed, we imported all the 
references found into Covidence software (44). All the process of duplicates, screening, 
data extraction and risk of bias analysis were performed by this web-based systematic 





Studies were considered eligible for the inclusion if they met the following criteria: 1) 
provided results that allowed comparing the MHO and MUO in regards to PA, SB, CRF 
and MST (aim 1) or provided risk estimates on longitudinal prognosis of MHNW and 
MHO for all-cause mortality, non-fatal CVD or CVD mortality after adjustments for 
PA, SB, CRF or MST (aim 2); 2) healthy participants without any illness that could 
influence their metabolic profile; and 3) original studies written in English or Spanish 
(excluding letters, meeting abstracts, systematic reviews and/or meta-analyses, etc.). To 
be included in the meta-analysis, studies additionally had to provide, for the aim 1, 
mean and standards deviations (or 95% confidence intervals, CI) and sample sizes for 
MHO and MUO group; and for the aim 2, hazard ratio (HR), odds ratio (OR) or relative 
risk (RR) and their 95% CI for all-cause mortality, non-fatal CVD or CVD mortality. 
When a cohort was represented in more than one study, we included only the study with 
the largest sample size. In Supplemental Material, Table S2 shows the studies that 
were excluded after revision of these inclusion criteria and the reasons for exclusion. 
Study Selection Process 
Two reviewers (CC-S and JHM) independently performed the study selection process. 
Firstly, the reviewers examined title and abstract of each article in order to identify those 
studies that could be included for the next step of the selection process (inter-reviewer 
agreement = 99%). Then, studies that appeared eligible based on the first screening were 
read full-text against the inclusion criteria for their final inclusion or exclusion in the 
systematic review (inter-reviewer agreement = 89%). Disagreements on the study 
selection were solved by reaching consensus between reviewers. When the inclusion of a 
study was ambiguous, a third reviewer (FBO) was included for resolving by discussion 
and a consensus decision was made.  
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Of the articles included in the systematic review, we meta-analyzed those studies that 
provided cross-sectional information (aim 1) on moderate-to-vigorous PA (MVPA), SB, 
CRF and/or MST, since these components were the most reported and most health-
related. Although the meta-analysis was conducted using MVPA data, we refer to PA in 
the text as general concept and for simplicity. Moreover, for MST, we analyzed the 
relative MST because previous studies have shown to be a stronger predictor of CVD risk 
factors than indicators of absolute strength (45,46), yet in the text we refer to just MST 
as general concept and for simplicity. Concerning the longitudinal studies (aim 2), we 
meta-analyzed those which adjusted for PA or CRF and presented all-cause mortality, 
non-fatal CVD or CVD mortality as outcomes. A minimum of three studies was requested 
to perform the meta-analysis. 
Data Collection Process 
Data extraction from eligible studies was performed by two reviewers (CC-S and JHM) 
using a consensual template with a third reviewer (FBO). The extracted data vary 
depending on the aim of the study: for the aim 1, we extracted 1) first author’s name and 
year of publication of the study, 2) Setting, study design and sample size, 3) age, 4) 
metabolic criteria used, 5) definition for classifying MHO or MUO, 6) outcomes of 
interest (measurement and unit), 7) statistical analysis used and adjustments, and 8) main 
findings of the studies included; for the aim 2, we additionally included years of follow-
up and number of all-cause mortality, non-fatal CVD and/or CVD mortality cases in the 
template.  
Quality of the Studies and Risk of Bias  
Study quality was assessed by two reviewers (CC-S and JHM) independently and using 
two different tools depending on the aim. Cross-sectional studies included in the aim 1 
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were evaluated following the Critical Appraisal Checklist for Analytical Cross-sectional 
studies from the Joanna Briggs Institute (47). The checklist consists of 8 items regarding 
inclusion criteria, study sample and setting, exposure measured, standard criteria for 
measurement, confounding factors, strategies to deal with confounders, outcomes 
measured and statistical analysis (Supplementary material 1). Each item was assessed 
as “yes”, “no”, “unclear” or “not applicable”.  For standardization, we considered “yes” 
as low risk of bias, and “no” and “unclear” as high risk of bias. Overall, low risk of bias 
(i.e., high quality study) was considered when a study accumulated at least 5 items 
answered as “yes”. Studies assessed as ‘yes’ in less than 5 items were categorized as high 
risk of bias (i.e., low quality study). 
Longitudinal studies were assessed by Newcastle Ottawa Scale (NOS) risk of bias tool 
(48). The NOS tool assesses the study quality of cohort studies in 8 items grouped in three 
categories: selection, comparability and outcome (Supplementary material 2). A study 
can be awarded a maximum of one star for each numbered item within the selection (i.e., 
items 1-4) and outcome categories (i.e., items 6-8), and a maximum of two stars in the 
comparability domain (i.e., item 5). Thus, each study can be awarded with a maximum of 
9 stars. Overall, low risk of bias (i.e., high quality study) was defined when a study got at 
least 6 stars. High risk of bias (i.e., low quality study) was then defined as studies awarded 
with less than 6 stars. 
Meta-Analysis 
The meta-analysis was performed in: 1) MHO vs. MUO groups for cross-sectional studies 
(aim 1), since the difference in fitness between obese individuals (both MHO and MUO) 
and normal-weight individuals is well-known (27); and 2) MHNW vs. MHO for 
longitudinal studies in the prognosis of all-cause mortality, non-fatal CVD and CVD 
mortality adjusting for CRF or PA (aim 2), since the differences in risk of disease between 
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MHO and MUO are well-known and was therefore not needed to be tested in this meta-
analysis. In order to answer the aim 1, we first calculated the mean difference between 
metabolic phenotypes’ groups (MHO minus MUO) and, then, its standardized mean 
difference (SMD, d-Cohen) and 95% confidence intervals (CI) on PA, SB, CRF and MST. 
The main analyses are presented with overweight and/or obese participants. Sensitivity 
analysis was performed with only the obese sample, and results are presented as 
supplementary materials. The pooled SMD in the outcomes analyzed was obtained using 
fixed or random effects models depending on the heterogeneity level detected (I2; the 
larger the value, the greater the heterogeneity). Heterogeneity was evaluated by the 
percentage of total variability attributed to between-study heterogeneity (I2 statistics). 
Low, moderate and high degrees of heterogeneity were identified as I2 values of 25, 50 
and 75%, respectively (49).  
For the aim 2, we extracted the HR and its 95% CI of all the studies included. All the 
studies had as reference group the MHNW, except the one from Ortega et al.(27) who 
presented the data having the MHO group as reference. For comparison purposes, the 
results extracted from Ortega et al.(27) were inverted. Likewise, most of the studies 
included provided the HR estimate except Appleton et al. (50) which provided OR. In 
this case, as the OR was close to 1 and the prevalence was lower than 5%, the OR and 
HR values are assumed to be similar and, thus, we included it in the analysis as HR as 
previously done in another meta-analysis (35). Therefore, pooled HR estimates were 
obtained for all-cause mortality, non-fatal CVD and CVD mortality outcomes using fixed 
or random models (depending on the I2 value).  
Funnel plots were also examined for assessing risk of potential publication bias. We also 
calculated the P value of the Egger’s intercept. The leave-one-out analysis helped to 
examine the influence of an article excluded on the combined SMD. If the evidence is 
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consistent on a certain finding, the leave-one-out analysis should not change the 
conclusions. 
All the statistical analyses were performed with the Comprehensive Meta-Analysis 







In total, 70 unique studies were included in the systematic review; 67 of them were 
included for the systematic review for aim 1. Among them, 55 studies (51-105) were 
focused on the differences between MHO and MUO in PA (N=53) and/or SB (N=9), 
while only 19 (5,27,55,72,81,86,89,94,97,106-115) compared CRF (N=19) and MST 
(N=6) between phenotypes. Seven studies presented both PA and SB data, while 
another 7 studies examined both PA/SB and fitness data. In regards to the aim 2, 11 
studies were included in the systematic review, 10 studies (50,60,70,77,82,91-
93,116,117) adjusted for PA in the association of MHO vs. MHNW with risk of all-
cause mortality, CVD mortality or non-fatal CVD, while only one study adjusted for 
fitness (27).  Figure 2 shows the flowchart of the study selection process. 
For meta-analysis purposes, a total of 25 unique studies that provided comparable data 
(or data that could be transformed into comparable data) were included for the aim 1, 
where most of the information was provided for CRF (N=19) 
(5,27,55,72,81,86,89,94,97,106-115). PA (N=6) (55-58,72,87), SB (N=5) 
(55,58,75,87,102) and relative MST (N=6) (55,81,106,107,110,115), were also analyzed 
(Figure 2). For the aim 2, a total of 10 unique studies adjusting for PA were included in 
the meta-analysis (50,60,70,77,82,91-93,116,117). We did not perform a meta-analysis 
with studies adjusting for CRF, since we found only one study doing this adjustment 
(27). The meta-analysis on studies adjusting for PA examined the following outcomes: 
all-cause mortality (N=4) (60,92,93,117), non-fatal CVD and CVD mortality (N=7) 




Characteristics of the Study Sample 
The characteristics of the 67 unique studies included in the systematic review for the 
aim 1 are shown in supplementary material Table S3. Studies reporting estimates for 
PA and/or SB ranged in sample size from 8 to 342,442 participants. The mean age for 
these studies ranged from 11.8 to 72 years-old. PA and SB were mainly self-reported 
(N=47 and N=6, respectively). Few studies examined PA and SB by objective 
measurements such as accelerometers or pedometers (N=9 and N=4, respectively). For 
fitness, sample size ranged from 8 to 3,911 (mean age ranged from 14.1 to 61.1 years-
old). CRF was the most reported fitness component (N=19), followed by muscular 
strength (N=6). Less articles were found studying other components of fitness, i.e., 
speed-agility (N=2), flexibility (N=2) and/or balance (N=1).  
Table 1 shows the characteristics of the study samples of 11 unique studies included in 
the systematic review for aim 2. Sample sizes of the studies included ranged from 72 to 
65,175 participants. The duration of the follow-up ranged from 8 to 14 years. Of the 
studies that examined all-cause mortality, the number of cases ranged from 9 to 449. 
The number of cases from non-fatal CVD and CVD mortality ranged from 2 to 261.    
Quality of the Studies and Risk of Bias 
The analysis of the quality of the studies, i.e., risk of bias, included in the systematic 
review and meta-analysis can be found in Figure 3 for cross-sectional and longitudinal 
studies. The specific information with the scoring of each study in each item and total is 
shown in supplementary material Table S4 for cross-sectional studies and Table S5 
for longitudinal studies. Overall, 80% of the cross-sectional studies included for the aim 
1 were scored as high-quality studies, indicating a low risk of bias in most of the studies 
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included. Likewise, all of the longitudinal studies (i.e., 100%) included for the aim 2 
were scored as high-quality studies, indicating a low risk of bias in the studies included. 
Differences in PA, SB, CRF and MST Between MHO and MUO 
Figure 4 depicts the meta-analyzed differences between MHO and MUO for PA 
(SMD= 0.267, 95% CI: 0.090, 0.444, P=0.003, I2= 48.3%, total N=5539) and SB 
(SMD= -0.199, 95% CI: -0.317, -0.081, P=0.001, I2= 44.6%, total N=5290). There was 
no publication bias for any of the outcomes studied (PA, Egger’s test, p=0.534; SB, 
Egger’s test, p=0.944; supplementary material Figure S1). Sensitivity analyses also 
showed significant differences between MHO and MUO when only obese sample were 
analyzed (PA, SMD= 0.635, 95% CI: 0.178, 1.091, P=0.006, I2= 77.7%; and SB, SMD= 
-0.175, 95% CI: -0.281, -0.070, P=0.001, I2= 30.7%; supplementary material Figure 
S2). Egger’s tests indicated no significant publication bias (all P≥0.473, supplementary 
material Figure S3). The leave-one-out analysis did not alter the results (data not 
shown). 
The meta-analysis of the differences between MHO and MUO showed a significant 
difference in CRF in favor of MHO (SMD=0.317, 95% CI: 0.232, 0.402, P<0.001, I2= 
49.1%, total N=11758) (Figure 5). In regards to MST, no significant difference was 
observed between MHO and MUO (SMD= -0.049, 95% CI: -0.241, 0.143, P=0.618, I2= 
0%, total N=851). There was no significant publication bias according to Egger’s test 
both for CRF (p=0.224, supplementary material Figure S4a) and MST (p=0.393, 
supplementary material Figure S4b). In sensitivity analyses, we observed that these 
findings persisted when the analyses were restricted to obese participants (i.e., 
excluding overweight participants from the analyses) (CRF, SMD= 0.276, 95% CI: 
0.206, 0.346, P<0.001, I2= 29.2%; and MST SMD= -0.126, 95% CI: 0.389, 0.138, 
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P=0.351, I2= 0%; supplementary material Figure S5). No publication bias was 
observed (Egger’s test ≥0.729; supplementary material Figure S6).  
Prognosis of MHO After Considering PA   
After adjustment for PA, no significant differences were observed between MHO and 
MHNW in the risk of all-cause mortality (HR= 1.32, 95% CI: 0.833, 2.108, P=0.235, 
I2= 73.0%, total N=93.561; Figure 6a). No significant publication bias was observed 
(Egger’s test, P=0.601, supplementary material Figure S7a). However, the leave-one-
out analysis by omitting one study (i.e., Sung et al. (92)) turned the HR from non-
significant to significant (HR= 1.58, 95% CI: 1.205, 2.076, P=0.001, data not shown in 
figures). The meta-analysis focused on CVD showed that MHO individuals presented a 
24% higher risk of non-fatal CVD and CVD mortality than MHNW individuals (HR= 
1.24, 95% CI: 1.071, 1.444, P=0.004, I2= 0%; Figure 6b).  However, in the leave-one-
out analysis (i.e., omitting Lassale et al. (77)), we observed that the HR became non-
significant (HR= 1.21, 95% CI: 0.983, 1.492, P=0.073, data not shown in figures). No 
publication bias was observed (supplementary material Figure S7b). A sensitivity 
analysis was performed considering only those studies that examined non-fatal CVD 
(data not shown). The result was similar, showing that MHO presented 26% higher risk 
of non-fatal CVD compared to MHNW (HR= 1.26, 95% CI: 1.084, 1.474, P=0.003, I2= 
0%). The Eggers’ test did not show significant publication bias either.  
Exploratory analyses stratifying the analysis by the studies with a follow-up <10 years 
and ≥10 years (supplementary material Figure S8), showed that there were not 
differences in the pooled HR for CVD mortality and non-fatal CVD, i.e., HR= 1.24 for 




Prognosis of MHO After Considering CRF  
After excluding one study using a smaller sample (118) from a cohort already included 
(27), only one study examined the prognosis of MHO after adjustment for CRF (27), 
not being therefore applicable for use in  the meta-analysis. Nevertheless, for the 
purpose of this article, we re-analyzed (changed the reference group from MHO in the 
original paper to MHNW in this review) the original data used in this study and crafted 
Figure 7, which shows the role of CRF in the prognosis of MHO. We observed a 
markedly higher risk in the MHO group in all-cause mortality, non-fatal CVD and CVD 
mortality compared with the MHNW group, independent of a set of potential 
confounders. However, this risk was strongly attenuated and became non-significant 
after additional adjustment for CRF for the 3 outcomes studied. These findings were 






In the present systematic review and meta-analysis, we focused on two relevant topics 
related to the MHO phenotype, its characterization (aim 1) and prognosis (aim 2). The 
studies included in this review were mostly (80-100%) scored as high-quality studies 
indicating a low risk of bias in the findings obtained. We found 67 studies examining 
differences between MHO and MUO in PA, SB, CRF and MST. Our meta-analysis 
showed that MHO individuals have significantly higher levels of PA and CRF and 
lower levels of SB than MHO individuals, without differences in MST between these 
phenotypes. In addition, we found 10 unique longitudinal studies examining the 
prognosis of MHO compared to MHNW after accounting for PA, only one study (after 
excluding another one from the same cohort that used a smaller sample) accounting for 
CRF, and none accounting for SB or MST. The meta-analysis of 10 studies accounting 
for PA showed marginally non-significant higher (33%, CI=0.83-2.11) risk in MHO in 
the risk of all-cause mortality, and a marginally significant higher (24%, CI=1.07-1.44) 
risk of CVD mortality and non-fatal CVD compared to MHNW. However, the leave-
one-out analysis showed that the effect sizes observed were slightly decreased or 
increased, changing the pooled effect from non-significant to significant for all-cause 
mortality and vice versa for CVD outcomes. In addition, we did not observe a different 
effect size in studies with shorter (<10 years) or longer (≥10 years) of follow-up, yet the 
number of studies was limited. Altogether, the findings from the present meta-analysis 
in studies adjusting for PA support the notion that the differences between MHO and 
MHNW in the risk of future all-cause mortality and CVD mortality/morbidity are 
borderline significant/non-significant, independently of the length of the follow-up. 
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The present systematic review identified only one unique study which adjusted for the 
potential confounding effect of CRF (27). This study observed that after adjustment for 
a set of potential confounders except for CRF, MHO had a significantly increased risk 
of all-cause mortality, non-fatal CVD and CVD mortality. However, this risk became 
markedly attenuated and non-significant, after additional adjustment for CRF.  
Differences in PA, SB, CRF and MST Between MHO and MUO 
Previous narrative reviews have pointed out that a higher level of PA and CRF seemed 
to be a characteristic of MHO when compared to MUO individuals 
(8,26,28,29,119,120). The present systematic review and meta-analysis has quantified, 
for the first time, the existing evidence in this regard and statistically tested whether 
these differences between MHO and MUO are significant. In addition, since longer time 
spent in SB and low levels of MST have also shown to predict a higher risk of 
metabolic disorders and CVD risk (15-17,20-24), we included them as well in our 
systematic search. The results from the present meta-analysis support that MHO have 
higher levels of PA, lower levels of SB and higher levels of CRF, without differences in 
MST, suggesting that these factors could be contributing to the better metabolic profile 
of the MHO phenotype. The largest differences were observed in CRF, followed by PA 
and then by SB.  
Prognosis of MHO After Considering PA 
Even if the present meta-analysis restricted the systematic search only to studies 
adjusting for PA, we were able to retrieve 5 new cohort studies adjusting for PA 
(59,60,77,117,121) not included in the previous meta-analyses (35,37-39). The pooled 
risk observed was higher for all-cause mortality (33%) and for CVD 
mortality/morbidity (24%) in MHO compared to MHNW. This risk was borderline 
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significant/non-significant and seems to be lower than the 45 to 60% higher risk of 
CVD morbidity reported in the meta-analysis by Eckel et al. (37) and Zheng et al. (35) 
respectively, which included all studies focused on MHO, not only those adjusting for 
PA as ours. The lower risk observed in our analysis of studies adjusting for PA seems to 
support that the well-known differences in PA existing between obese and normal-
weight individuals (and therefore also between MHO and MHNW) could explain, at 
least partially, the difference between the risk observed in our meta-analysis and that 
observed in most of the literature (not adjusting for PA) for CVD mortality/morbidity. 
However, this should be interpreted cautiously, and to definitively test this hypothesis, 
more studies are needed showing the effect sizes before and after additional adjustment 
for PA, and then meta-analyze them. 
Kramer et al. (39), and Fan et al.(38), observed a distinct risk between studies with 
shorter or longer follow-ups, i.e., HR=1.19 (all studies) vs. 1.24 (longer follow-up) and 
HR=1.05 (shorter follow-up) vs. 1.60 (longer follow-up), respectively; however, we did 
not observe that difference in our study, i.e., HR= 1.24 vs. 1.24 for studies with less 
than 10 years vs. equal or more than 10 years of follow-up, respectively (using the 10 
years cut-point, as in the study by Kramer et al. (39)).   
Different definitions to classify metabolic phenotypes have been used, being the most 
commonly used in relation to the number of MetS criteria met, i.e., ≤2 criteria (few 
studies), ≤1 criteria (most commonly used in a near past) and 0 criteria (new and most 
currently accepted definition) (8). It has been argued that a person should not be 
classified as “metabolically healthy” if that person has T2DM or HTN, as an example. 
Therefore, based on this sound reasoning, meeting ≤1 or ≤2 criteria of MetS are not 
recommended any longer to define MHO. However, the problem is that most of existing 
evidence on the prognosis of MHO is based in studies that used these definitions. In our 
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present meta-analysis 3 (92,93,117) out of cohorts available used this newer and more 
accepted definition of meeting 0 criteria for all-cause mortality, and 1 out of 7 available 
for CVD mortality/morbidity. The pooled effect for all-cause mortality outcome would 
remain non-significant if conducted only in these 3 cohort studies, and the only 1 study 
for CVD outcomes does not allow a meaningful meta-analysis. Nevertheless, it is 
expected that the prognosis of MHO will be better with this new/current definition (37), 
since individuals classified as MHO will be “healthier” than with the older definitions, 
and so seems to support our systematic review, since the study by Sung et al. (92) 
showed by far the lowest risk of CVD mortality (HR=0.4) in MHO compared to 
MHNW, yet the sample size of this study was small, and we found no other studies to 
test this hypothesis in CVD mortality/morbidity.  
Prognosis of MHO After Considering CRF 
Given the strong and consistent association of CRF with metabolic risk, all-cause 
mortality and CVD mortality/morbidity (14,18,19,24), and given also the large 
difference existing in CRF between obese and normal-weight individuals, which as 
expected translate to differences in CRF between MHO and MHNW (27,28), there is a 
good rationale that adjusting for CRF could potentially change the conclusions about 
the prognosis of the MHO. In this context, the only study accounting for the potential 
influence CRF is our study using the Aerobics Center Longitudinal Study (ACLS) data 
(27). This study supports the notion that the differences in risk of all-cause mortality 
and CVD mortality/morbidity observed in the literature could be explained by the 
differences in CRF between MHO and MHNW. However, future cohort studies 
accounting for CRF in their models will confirm or contrast these findings. Since BMI 
is often criticized as a marker of adiposity, we tested the same hypothesis using accurate 
methods (hydrostatic weighing and skinfold thicknesses) to define obesity based on 
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body fat percentage and the results were consistent (27), making this conclusion 
stronger. Compared to PA, we expected CRF to show a stronger reduction of risk in 
MHO vs. MHNW (122), and so seems to support the findings of this systematic review, 
yet given the limited information including CRF found, this hypothesis on MHO 
prognosis needs to be confirmed in future cohort studies. 
Limitations and Strengths 
This study presents several limitations. First, although two major databases (i.e., 
PubMed and Web of Science) were used for the search, the no inclusion of other 
electronic databases such as EMBASE should be acknowledged as a limitation. Second, 
the use of different definitions of MHO and different ways of measuring PA or SB, 
could explain the high degree of heterogeneity observed among the studies analyzed. 
Thus, the use of the harmonized definition of the MHO and the use of objective 
methods for PA and SB, will allow more solid conclusions on this topic. Third, the low 
number of studies reporting the results without and with additional adjustment for PA or 
CRF did not allow us to meta-analyze how this can influence the prognosis of all-cause 
mortality and CVD mortality/morbidity in the MHO compared to MHNW. Fourth, to 
increase the number of studies and power, we included studies that included overweight 
plus obesity in definition of MHO, but our sensitivity analyses (reported in 
supplementary material) showed consistent findings for all meta-analysis conducted, 
suggesting that the conclusions of the present meta-analysis are valid for MHO when 
including or excluding overweight. 
Despite of these limitations, to the best of our knowledge, this is the first meta-analysis 
focused on the differences between MHO and MUO in PA, SB, CRF and MST 
outcomes, as well as, examining the role of PA and CRF in the prognosis of all-cause 
mortality and non-fatal CVD. The thorough and complete methods used in this meta-
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analysis should be acknowledged, e.g., double examination of the selection process by 
two independent reviewers, the assessment of the studies’ quality and risk of bias 
(Joanna Briggs Institute and NOS checklists), funnel plots and Egger’s tests for testing a 
potential publication bias, the leave-one-out analysis, etc. 
Practical Implications 
Based on the findings presented in this meta-analysis, future description and 
characterization of the MHO phenotype, when compared with the rest of obese patients 
(i.e., MUO), should include a higher CRF as a significant factor, but also a longer time 
spent in PA, particularly MVPA (that is what was analyzed in the present meta-
analysis), and shorter time spent in SB. The fact that MHO and MHNW individuals 
differed in these lifestyle factors and attribute, does not imply causality. Future 
intervention studies aiming to increase the time spent in PA, reduce the time spent in SB 
and enhance CRF will test the effectiveness of such intervention in turning MUO into 
MHO. Of course, in an ideal world, the best scenario possible would be a transition 
from MUO to MHNW, which would have a huge benefit on multiple health indicators. 
However, reality shows that most of existing lifestyle interventions have failed to 
maintain the weight losses in the long term, with bariatric surgery being the most 
effective long-term treatment for patients with more severe obesity (123). In this 
context, Stefan and colleagues (123) have suggested that for people with obesity, to 
become normal-weight, should be a longer-term goal, but they should be encouraged to 
follow a healthy lifestyle in order to improve their metabolic profile, i.e., become (or 
remain) MHO as perhaps a more achievable and shorter term goal (what they named as 
the “low-hanging fruit”). Building on this idea, our meta-analysis suggests that PA and 
CRF seems to play a protective role in the prognosis of MHO, and they should be 
targeted in lifestyle interventions, together with other lifestyle factors, such as diet, to 
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treat MUO and hopefully transition them into people with a healthier metabolic profile, 




Our systematic review and meta-analysis provides novel insights in the characterization 
and prognosis of the MHO phenotype. First, the meta-analysis on cross-sectional studies 
supports that MHO individuals are more active, spent less time in SB, and have a higher 
level of CRF (yet no differences in MST) than MUO individuals, suggesting that their 
healthier metabolic profile could be, at least partially, due to these healthier lifestyle 
factors and attributes. Second, the findings from the present meta-analysis of cohort 
studies, which accounted for PA, support the notion that MHO individuals have a 24-
33% higher risk of all-cause mortality and CVD mortality/morbidity compared to 
MHNW individuals. This risk seems to be borderline significant/non-significant and 
independent of the length of the follow-up in our meta-analysis. This risk was lower 
than that reported in previous meta-analyses which included all studies focused on 
MHO participants (i.e., 45-60% higher risk in MHO) (35,37), that could be indicating a 
modest reduction in the risk estimates once PA is accounted for. Third, only one study 
(27) has examined the role of CRF in the prognosis of MHO individuals. This study 
suggests that the differences in the risk of all-cause mortality and CVD 
mortality/morbidity between MHO and MHNW are largely explained by differences in 
CRF between these two groups, supporting the idea that gathering information about the 
metabolic and CRF status in clinical settings could improve risk stratification in obese 
patients. Collectively, from a clinical and public health point of view, our meta-analysis 
indirectly support that obesity treatment efforts should be targeted not only on losing 
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weight, but also on improving CRF through lifestyle programs focused on increasing 
PA levels along with other healthy lifestyle factors. 
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Table 1. Longitudinal studies examining the differences between MHNW and MHO after further adjustment of PA OR physical fitness (N=11). 
Author, year Setting  
Study design and 
years of follow-up 

















follow-up: 8.2 years 
Random sample 
N = 2315 
 
Subgroups: 
NMHNW = 636 




- HDL< 1.0♂ / 1.3♀mmol/l  
- TG ≥ 1.7 mmol/l  
- SBP ≥ 130 mmHg  
- DBP ≥ 85 mmHg 
- Glucose ≥ 5.6 mmol/l 
MHO/MHNW: ≤1 








NMHNW = 25 








level, LDL and PA 
Compared with the MHNW group, 
MHO did not show an increase in 
CVD/stroke cases after adjustment 
for confounders (OR: 1.16, p>0.05). 
 
Bo et al, 2012 Asti (Italy) 
Longitudinal, 
follow-up: 9 years 
Not specified 
N = 1658 
 
Subgroups: 
NMHNW = 540  
NMHO = 72 
 
53.6 (5.6) - WC ≥ 94♂ / 80♀ cm  
- TG ≥ 1.7 mmol/L 
- HDL < 1.0♂ / 1.3♀mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  













-Model 1: adjusted 





MHO showed higher incident in 
hyperglycemia and CVD cases than 
in MHNW (HR:2.16 and 2.76, 
respectively) 
Doustmohamadian 
et al, 2017 
Tehran Lipid and 
Glucose Study  
Longitudinal, 
follow-up: 8 years 
Random sample 
N = 8804 
 
Subgroups: 
NMHNW = 2086  
NMHOO = 1125 
47.7 (12.6) - HDL < 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 100 mg/dL 










(i.e. ≥ 89 cm for 






NMHNW = 65  







-Model 2: adjusted 
for age and sex 
 
-Model 3: adjusted 
for model 1 plus 
In unadjusted model, MHO presented 
higher risk of mortality for all-cause 
than MHNW (HR: 1.65, p<0.05). 
However, after adjustment for either 
model 2 or 3, they did not find 
significant differences between MHO 
and MHNW (Model 1, HR: 1.21; 












follow-up: 8.1 years 
Random sample 
N = 6215 
 
Subgroups:: 
NMHNW = 1555  
NMHO = 408 
47.4 (0.2) -WC > 89♂ / 91♀ cm 
- HDL < 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL  
- SBP ≥ 140 mmHg 
- DBP ≥ 85 mmHg 
- Glucose ≥ 100 mg/dL 
 
MHO/MHNW: ≤1 
of the criteria met 
(excluding WC) 
CVD cases CVD cases: 
NMHNW = 64  
NMHO = 13 
HR 
 
-Model 1: adjusted 
for age and sex 
 
-Model 2: adjusted 




high TC and VPA 
 
No significant differences were 
observed in the incidents for CVD 
between MHO and  MHNW after 
adjusted for confounders (Model 1, 
HR: 1.01; model 2, HR: 1.07, p>0.05) 
Ortega et al, 2013 ACLS 
United States 
Longitudinal, 
follow-up: 14.3 (for 
mortality), 7.9 (non-





All-cause and CVD 
mortality 
NMHNW = 16002 
NMHO = 1738 
 
Non-fatal CVD cases 
NMHNW = 7001 
NMHO = 544 
 
44.2 (9.9) - HDL≤ 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥100 mg/dL 
 
Note: in the paper they 
provided results from 
obese categorized based 
on their BF%. For more 
information see the paper 
MHO/MHNW: ≤1 










NMHNW = 449  




NMHNW = 98  




NMHNW = 261  





-Model 1: adjusted 




parental history of 
CVD (this last 
confounder were 
removed for cancer 
mortality analyses) 
 
-Model 2: Model 1 
plus CRF 
In all-cause mortality, no significant 
difference was observed between 
MHO and MHNW participant (Model 
2, HR: 0.91). This result was 
consistent for CVD mortality and 
incident non-fatal CVD, as well as for 
cancer mortality after adjustment for 
the set of confounders including 
fitness (HR: 0.73, 0.78 and 0.61, 
respectively). 
Song et al, 2007 Women’s Health 
study 
United States 
54.3 (6.5) - HDL < 50 mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 135 mmHg 
MHO/ MHNW: 
≤2 of the criteria 
met 
- CVD cases 
- CHD cases 
-Stroke cases 
-CVD cases 
NMHNW = 278 
NMHO = 77 
RR 
 
MHO showed similar risk of CVD as 










NMHNW = 12943 
NMHO = 2925 
- DBP ≥ 85 mmHg  




- CHD cases 
NMHNW = 149 
NMHO = 55 
 
- Stroke cases 
NMHNW = 129 
NMHO = 22 
 
 
-Model 1: adjusted 
for age and vitamin 
E and aspirin. 
 









parental history of 
myocardial 
infarction, BMI and 
PA 
 
adjusted for model 2 (RR: 1.05). The 
RR of MHO in model 1 was 1.36. 
 
In regards to CHD, the MHO showed 
higher RR than MHNW (Model 1, 
RR: 1.80; model 2, RR: 1.25). 
 
MHO showed lower RR of stroke 
cases than MHNW in both models 
examined (Model 1, RR: 0.85; model 
2, RR: 0.82). 
 
 











NMHO = 12731 





NMUO = 15906 
 
40.2 (10) - SBP ≥ 140 mmHg 
- DBP ≥ 90 mmHg  
- Glucose ≥ 126 mg/Dl 
MHO/MHNW: 








NMHNW = 212  
NMHO = 39  
-CVD 
mortality: 
NMHNW = 21  




-Model 1: adjusted 
for age and sex 
 






diabetes, HTN and 
a history of CVD 
and PA 
For both all-cause and CVD 
mortality, there was no significant 
difference between MHO and 
MHNW (HR~0.70 for all-cause 
mortality and HR~0.40 for CVD 
mortality for both models, p>0.05) in 
any of the models examined.  
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NMHO = 1103 
52.4 (not 
specified) 
- WC ≥ 94♂ / 80♀ cm  
- HDL < 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥100 mg/dL 
MHO/MHNW: ≤2 
of the criteria met 
 
CHD cases -CHD cases: 
NMHNW = 
1978  
NMHO = 360 
 
HR 





alcohol intake and 
PA 
MHO presented higher risk of CHD 
cases than MHNW (HR: 1.28, 
p=0.02) 











NMHNW = 879 




- HDL< 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  




none of the 







NMHNW = 26  





-Model 1: adjusted 




-Model 2: Model 1 
plus meeting PA 
guidelines 
MHO presented higher risk of 
mortality for all-cause than MHNW 
(HR: 2.48, p=0.02) after adjustment 
for model 1. When adding meeting 
MVPA guidelines, result was 
unchanged (HR: 2.41). 
Moon et al, 2017 KoGES study 
Korea (Asia) 
Longitudinal, 





NMHNW = 2929 
NMHO = 1262 
50.6 (not 
specified) 
- HDL ≤ 1.03♂ / 1.30♀ 
mmol/L 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 100 mg/dL 
MHO/MHNW: ≤1 
of the criteria met 
 
CVD cases CVD cases: 
NMHNW = 135  




-Model 1: adjusted 
for age and sex 
 
-Model 2: adjusted 






MHO participants were not at 
elevated risk of CVD compared with 
their MHNW counterparts after 
adjustment for confounders (Model 1, 






















NMHNW = 4799  
NMHO = 737  
42.8 (10.5) - WC ≥ 102♂ / 88♀ cm 
- HDL < 1.0♂ / 1.3♀ 
mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 5.6 mmol/L 
- TC ≥ 6.5 mmol/L 
 
MHO/MHNW: 









NMHNW = 82  




-Model 1: Age and 
sex  
 







MHO had higher risk of all-cause 
mortality than MHNW individuals 
(model 1, HR: 1.62; model 2, HR: 
1.66). 
♂: males, ♀: females, BMI: body mass index, WC: waist circumference, TG: triglycerides, TC: total cholesterol, HDL: high-density lipoprotein cholesterol, LDL: low-density lipoprotein 
cholesterol, SBP: systolic blood pressure, DBP: diastolic blood pressure, HTN: hypertension, MHNW: metabolically healthy normal weight, MHO: metabolically healthy obese, CRF: 
cardiorespiratory fitness, PA: physical activity, CVD: cardiovascular disease, CHD: coronary heart disease, CAD: coronary artery disease, HR: hazard ratio, OR: odds ratio. 
Note:  
-N sample include all participants in the study (not only those stated in the subgroups), thus, in some cases the first sample size provided in the setting-study design column is higher than the sum 




Figure 1. Number of publications focused on MHO/MUO during recent years.  
MHO: Metabolically healthy obesity. MUO: Metabolically unhealthy obesity. Terms included for this search are 
provided as Supplementary material Table S1. 
  
Year of publication






























































More than 11,500 
articles published 






Figure 2. Flow diagram of studies included through the review process according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)(43).  
*Studies were classified both in fitness and PA/SB outcomes, N=7. 
†Studies were classified both for aim 1 and 2, N=8. 
PA: Physical activity. SB: Sedentary behaviors. Adj.: adjusting. CRF: cardiorespiratory fitness. MST: relative 





Figure 3. Stacked bar plot showing the risk of bias assessed in all cross-sectional and 
longitudinal studies included in the systematic review and meta-analysis.  
 
The checklist used for risk of bias assessment for cross-sectional and longitudinal studies can be found in 
Supplementary material 1 and 2, respectively. *Total risk of bias was considered ‘low’ if cross-sectional studies 
accumulated at least 5 items (total = 8 items) answered as ‘yes’ or longitudinal studies awarded at least 6 stars (total = 
9 stars). The specific information with the scoring of each study in each item and total is shown in Table S4 for cross-





Figure 4. Forest plot of moderate-to-vigorous physical activity (Panel A) and sedentary 
behavior (Panel B) differences (pooled standardized mean difference) between 
metabolic phenotypes in overweight/obese participants.  
*Studies combining overweight and obese participants. Standardized mean difference are expressed as MHO minus 
MUO, thus, positive values represents that MHO showed higher values than MUO. The leave-one-out analysis did 
not alter the pooled estimate. MHO: metabolically healthy obesity. MUO: Metabolically unhealthy obesity. MVPA: 







Figure 5. Forest plot of cardiorespiratory fitness (Panel A) and muscular strength (Panel 
B) differences (pooled standardized mean difference) between metabolic phenotypes in 
overweight/obese participants.  
*Studies combining overweight and obese participants. Standard differences in means are expressed as MHO minus 
MUO, thus, positive values represent that MHO showed higher values than MUO. The leave-one-out analysis did not 
alter the pooled estimate. MHO: metabolically healthy obesity. MUO: Metabolically unhealthy obesity. CRF: 




Figure 6. Forest plot of metabolically healthy normal weight participants for the risk of 
all-cause mortality (Panel A) and non-fatal cardiovascular disease and cardiovascular 
disease mortality (Panel B) compared with metabolically healthy obese individuals after 
adjusting for physical activity.  
Hazard ratio is presented having metabolic healthy normal weight phenotype as reference (1). The leave-one-out 
analysis showed that the effect sizes observed were slightly decreased or increased, changing the pooled effect from 
non-significant to significant for all-cause mortality and vice versa for CVD outcomes (see exact estimates in the text, 




Figure 7. Role of cardiorespiratory fitness (CRF) on the prognosis of all-cause mortality and cardiovascular disease (CVD) of metabolically 
healthy obesity (MHO) men and women compared to metabolically healthy normal-weight (MHNW) or normal-fat (MHNF) men and women 
from the Aerobics Center Longitudinal Study (ACLS, N= 43,265 adults).  
This figure has been newly created for the purpose of this review, using the data presented in tables as well as methods and models described in detail by Ortega et al., 2013 (32 ). The major 
change from the original article is that here we set the MHNW/MHNF group as reference in the models instead of the MHO group as in the original paper, for an easier interpretation of the role 
of fitness.  *Model 1 is adjusted for age, sex, examination year, smoking, alcohol consumption and parental history of CVD.  Non-fatal CVD events include: myocardial infarction, stroke, and 
















Supplementary material 1. Tool used to assess the study quality and risk of bias of 
cross-sectional studies. 
Checklist for analytical cross-sectional studies from The Joanna Briggs Institute: 
1. Were the criteria for inclusion in the sample clearly defined?  
2. Were the study subjects and the setting described in detail?  
3. Was the exposure measured in a valid and reliable way?  
4. Were objective, standard criteria used for measurement of the condition?  
5. Were confounding factors identified?  
6. Were strategies to deal with confounding factors stated?  
7. Were the outcomes measured in a valid and reliable way?  




Supplementary material 2. Tool used to assess the study quality and risk of bias of 
longitudinal studies. 
Newcastle Ottawa Scale for cohort studies: 
Selection 
1) Representativeness of the exposed cohort       
 * a) Truly representative of the average _______________ (describe) in the 
community  
 *  b) Somewhat representative of the average ______________ in the community 
   c) Selected group of users eg nurses, volunteers 
   d) No description of the derivation of the cohort 
2) Selection of the non-exposed cohort  
 * a) Drawn from the same community as the exposed cohort  
   b) Drawn from a different source 
   c) Selected group of users eg nurses, volunteers 
   d) No description of the derivation of the non-exposed cohort 
3) Ascertainment of exposure 
 * a) Directly measured physical activity by accelerometers or cardiorespiratory 
fitness by gas exchange measurement  
 *  b) Physical activity measured by pedometers or physical fitness by field-based 
tests 
   c) Physical activity or fitness measured with self-reports 
 d) No description      
4) Demonstration that outcome of interest was not present at start of study 
 * a) Yes  
   b) No 
 
Comparability  
5) Comparability of cohorts on the basis of the design or analysis    
 * a) Study controls for physical activity/physical fitness 
 *  b) Study controls for any additional factor 
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Outcome            
       
6) Assessment of outcome 
 * a) Independent blind assessment  
 *  b) Record linkage 
   c) Self-report 
 d) No description      
7) Was follow-up long enough for outcomes to occur 
 * a) Yes (≥ 5 years) 
   b) No 
8) Adequacy of follow up of cohorts 
 * a) Complete follow up - all subjects accounted for  
 *  b) Subjects lost to follow up unlikely to introduce bias - small number lost ≥ 80 
% follow up, or description provided of those lost. 
   c) Follow up rate < 80% and no description of those lost 




Table S1. Search terms combined used for this systematic review in each database and 
number of studies found, and search term used for the purpose of Figure 1. 
Systematic review-PubMed (N=3270) 
(("cardiorespiratory fitness”[Title/Abstract] OR cardiorespiratory fitness [MeSH] OR 
"aerobic capacity”[Title/Abstract] OR "aerobic fitness” [Title/Abstract] OR "physical 
fitness”[Title/Abstract] OR "functional capacity”[Title/Abstract] OR "physical 
characteristic*”[Title/Abstract] OR "oxygen consumption”[Title/Abstract] OR 
"vo2max” [Title/Abstract] OR "vo2peak” [Title/Abstract] OR fitness[Title/Abstract] 
OR “physical activity”[Title/Abstract] OR “motor activity” [Title/Abstract] OR motor 
activity [MeSH] OR “exercise” [Title/Abstract] OR exercise [MeSH]) AND 
("metabolically healthy"[Title/Abstract]  OR "metabolically 
abnormal"[Title/Abstract]  OR "metabolically unhealthy"[Title/Abstract]  OR 
"metabolic profile"[Title/Abstract]  OR "metabolic syndrome"[Title/Abstract]  OR 
"metabolic syndrome"[MeSH]  OR "metabolically phenotype"[Title/Abstract]  OR 
“metabolically benign” [Title/Abstract]  OR “metabolic* benign” [Title/Abstract] OR 
“Obesity, Metabolically Benign”[Mesh] OR "metabolic* healthy"[Title/Abstract]  OR 
"metabolic* abnormal"[Title/Abstract] OR "metabolic* unhealthy"[Title/Abstract] 
OR "metabolic* phenotype"[Title/Abstract]  OR mho[Title/Abstract]  OR 
muo[Title/Abstract]  OR muho[Title/Abstract]  OR mao[Title/Abstract]) AND 
(“overweight” [Title/Abstract] OR “overweight” [Mesh] OR “Obese” [Title/Abstract] 
OR obesity[Title/Abstract] OR “obesity”[Mesh])) 
Systematic review-Web of science (N=6308) 
(("cardiorespiratory fitness” OR "aerobic capacity” OR "aerobic fitness” OR 
"physical fitness” OR "functional capacity” OR "physical characteristic*” OR 
"oxygen consumption” OR "vo2max” OR "vo2peak” OR fitness OR “physical 
activity” OR “motor activity”  OR “motor activities” OR “exercise” OR “exercises” 
OR “physical exercise” OR “acute exercise” OR “isometric exercise” OR “aerobic 
exercise” OR “exercise training”) AND ("metabolically healthy" OR "metabolically 
abnormal" OR "metabolically unhealthy" OR "metabolic profile"  OR "metabolic 
syndrome" OR "metabolic syndrome" OR “insulin resistance syndrome X” or 
“metabolic syndrome X” OR “dysmetabolic syndrome X” OR “Reaven syndrome X” 
OR “metabolic cardiovascular syndrome” OR "metabolically phenotype"  OR 
“metabolically benign” OR “metabolic* benign” OR "metabolic* healthy" OR 
"metabolic* abnormal" OR "metabolic* unhealthy" OR "metabolic* phenotype" OR 
mho  OR muo OR muho OR mao) AND (overweight OR Obese OR obesity)) 
Figure 1-Search in Pubmed 
("metabolically healthy"[Title/Abstract] OR "metabolically abnormal"[Title/Abstract] 
OR "metabolically unhealthy"[Title/Abstract] OR "metabolic profile"[Title/Abstract] 
OR "metabolic syndrome"[Title/Abstract] OR "metabolic syndrome"[MeSH] OR 
"metabolically benign"[Title/Abstract] OR "metabolic* benign"[Title/Abstract] OR 
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"Obesity, Metabolically Benign"[Mesh] OR "metabolic* phenotype"[Title/Abstract] 
OR mho[Title/Abstract] OR muo[Title/Abstract] OR muho[Title/Abstract] OR 
mao[Title/Abstract]) AND ("overweight"[Title/Abstract] OR "overweight"[Mesh] OR 
"Obese"[Title/Abstract] OR obesity[Title/Abstract] OR "obesity"[Mesh]) AND 





Table S2. Exclusion reasons for the studies not included in the systematic review and 
meta-analysis (N=55). 
Author, year Exclusion reason 
Amouzegar et al., 2015 Wrong outcomes 
Aparicio et al., 2014 Wrong study type 
Arsenault et al., 2009 Wrong study design 
Babu et al., 2014 Wrong study type 
Barbat-Artigas et al., 2012 Wrong outcomes 
Bell et al., 2015 Wrong outcomes 
Bjelakovic et al., 2017 Wrong outcomes 
Bradshaw et al., 2013 Wrong outcomes 
Brandon et al., 2017 Wrong outcomes 
Camhi et al., 2015 Wrong study design 
Chang et al., 2016 Wrong outcomes 
Chang et al., 2012 Wrong outcomes 
Choi et al., 2013 Wrong patient population 
Conus et al., 2004 Wrong patient population 
Corona et al., 2014 Wrong outcomes 
Dalleck et al., 2014 Wrong study type 
De Lorenzo et al., 2017  Wrong outcomes 
Delgado-Floody et al., 2018 Wrong outcomes 
Durward et al., 2012 Wrong study type 
Fung et al., 2015 Wrong comparator 
Gao et al., 2016 Wrong patient population 
Gayda et al., 2013 Wrong study type 
Gordon-Larsen et al., 2013 Wrong outcomes 
Gorostegi-Anduaga et al., 2018 Wrong patient population 
Guo et al., 2015 Wrong patient population 
Hamer et al., 2015 Wrong outcomes 
Hamer et al., 2012 Wrong comparator 
Henriques et al., 2015 Wrong outcomes 
Jae et al., 2014 Wrong study type 
Janiszewski et al., 2010 Wrong outcomes 
Kantartzis et al., 2011 Wrong outcomes 
Katzmarzyk et al., 2005 Cohort represented more than once 
Kelishadi et al., 2010 Wrong outcomes 
Khan et al., 2014 Wrong outcomes 
Kim et al., 2014 Wrong outcomes 
Kimokoti et al., 2014 Wrong outcomes 
Lee et al., 2009 Wrong outcomes 
Lee et al., 2018 Wrong outcomes 
Lopez-Garcia et al., 2013 Wrong study type 
Lwow et al., 2011 Wrong outcomes 
Manu et al., 2012 Wrong outcomes 
Messier et al., 2010 Wrong outcomes 
Nogueira et al., 2016 Wrong patient population 
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Rodriguez-Garcia et al., 2018 Wrong outcomes 
Rodriguez-Garcia et al., 2017 Wrong outcomes 
Ruhunuhewa et al., 2017 Wrong outcomes 
Ryu et al., 2015 Wrong study design 
St-Onge et al., 2004 Wrong patient population 
Stefan et al., 2008 Wrong outcomes 
Taylor et al., 2018 Wrong patient population 
Tomiyama et al., 2016 Wrong outcomes 
Twig et al., 2014 Wrong comparator 
Velho et al., 2010 Wrong study design 
Wedell-Neergaard et al., 2018 Wrong outcomes 






Table S3. Studies examining the differences between MHO and MUO on physical fitness and PA and sedentary behavior (N=67). 
Author, year Setting  
Study design 
Sample size 










Physical fitness (N=19)       
Aparicio et al, 
2014  
North of Morocco 
Cross-sectional 
Convenience sample 
N = 151 
 
Subgroups: 
NMHOO = 50 




52.5 (3.8) - WC ≥ 88 cm 
- HDL < 50 mg/dl  
- TG ≥ 150 mg/dl  
- SBP ≥ 130 mmHg  
- DBP ≥ 85 mmHg 
- Glucose ≥ 100 mg/l 
 
Note: in the paper they 
provided results from 
another definition. For 
more information see the 
paper 
MHOO: ≤ 1 of the 
criteria met 
(excluding WC) 







- CRF (6-min walk 
test, m) 
- Upper strength 
(handgrip, kg) 
- Lower strength 
(30-second chair 
stand, no. stands) 
- Upper flexibility 
(back scratch, cm) 
- Lower flexibility 
(chair sit-and-reach, 
cm) 
- Static balance 
(blind flamingo, no. 
fails) 




adjusted for age 
The MHOO group scored better than 
the MUOO group in CRF, (p<0.05), 
static balance and dynamic 
balance/agility (p<0.05 and p=0.004, 
respectively). No differences between 
groups were observed in muscular 
fitness and flexibility (all, p>0.05) 
Brochu et al, 2001  Not specified 
Cross-sectional 
Not specified 
N = 43 
 
Subgroups: 
NMHOO = 17 
NMUOO = 26 
 






- CRF (VO2peak in 
treadmill effort test, 
ml/kg·min) 
- PAEE (TEE·0.9 – 
RMR, Cal/day) 
T-test  MHOO and MUOO presented not 
significantly different values of 












NMHOO = 190 
NMUOO = 47 
NMHO = 24 
NMUO = 8 
14.7 (1.3) Age and gender- specific 
cut-off points by Jolliffe 
and Janssen (see article 
for more information) 
MHOO: ≤1 of the 
criteria met 
(excluding WC) 






MHOO: none of 
the criteria met 
(excluding WC) 




Note: The same 
criteria were 
applied when the 
analyses were 
done for MHO 
and MUO 
 
- CRF (VO2max in 
20m shuttle run test, 
ml/kg-min) 
- Lower and upper 
strength (relative 
handgrip and 
standing long jump 
test, kg and cm 
respectively) 
- Speed-agility 











No significant differences were 
observed in fitness in any of the 
analyses done with overweight/obese 
and only obese (including also the 
sensitivity analyses) (p>0.149) 





N = 61 
 
Subgroups: 
NMHO = 16 
NMUO = 21 
 
33.1 (5.3) - WC > 102♂ / 88♀ cm 
- HDL < 1.04♂ / 1.3♀ 
mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 6.1 mmol/L  
- HOMA > 3.46 
MHO: ≤ 2 of the 
criteria met  
MUO: ≥ 3 of the 
criteria met  
 
 
- CRF (VO2peak in 
treadmill effort test, 
ml/kg·min)  
- Lower strength 
(isometric extensor 
peak torque and 
extensor isokinetic 
total work, Nm/kg 
and J/kg),  










Both MHO and MUO groups had 
lower VO2peak than normal weight 
participants, and lower muscle 
strength and endurance, expressed by 
isometric extensor peak torque and 
extensor isokinetic total work. All 













NMHO = 55 
NMUO = 79 
 
52.8 (10.9) - HDL < 1.0♂ / 1.30♀ 
mmol/L 
- TG ≥ 1.70 mmol/L 
- SBP ≥ 130 mm Hg 
- DBP ≥ 85 mm Hg 
- Glucose ≥5.6 mmol/L 
 
MHO: ≤ 1 of the 
criteria met 
MUO: ≥ 2 of the 
criteria met 






MHO had significantly higher 
VO2peak compared with their 
MUO peers (p<0.01) 
Dobson et al, 2016  Liverpool (England) 
Cross-sectional 
Convenience sample 
N = 67 
 
Subgroups: 
NMHO = 21 
NMUO= 16  
 
49 (11) - WC > 102♂ / 88♀ cm  
- HDL < 1.04♂ / 1.3♀ 
mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 6.1 mmol/L  
MHO: ≤ 2 of the 
criteria met  
MUO: ≥ 3 of the 
criteria met  
 
  
- CRF (VO2max in 
treadmill effort test, 
ml/FFM·min) 
ANOVA There were no significant differences 
between the four groups in terms of 
CRF 
Gregorio-Arenas 




N = 228 
 
Subgroups: 
NMHO = 30 
NMUO = 40 
 
53 (5) - HDL < 50 mg/dL   
- TG ≥ 150 mg/dL  
- SBP ≥ 130 mmHg  
- DBP ≥ 85 mmHg  
- Glucose ≥ 100 mg/dL 
MHO: ≤ 1 of the 
criteria met  
MUO: ≥ 2 of the 
criteria met  
 
  
- CRF (6-min walk 
test, m)  
- Upper strength 
(handgrip, kg) 
- Lower strength 
(30-second chair 
stand, no. stands) 
- Upper flexibility 
(back scratch, cm) 
- Lower flexibility 
(chair sit-and-reach, 
cm) 









The 6-min walk and the back-scratch 
tests, for the measurement of CRF 
and upper flexibility, respectively, 
presented the most robust differences 










NMHO = 1631 
NMUO = 336 
 
48.9 (7.4) - HDL < 1.036 mmol/L 
- TG > 1.695 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose > 6.1 mmol/L 
MHO: ≤1 of the 
criteria met 
MUO: ≥ 2 of the 




- CRF (VO2peak in 











MHO showed higher CRF compared 
to those with a metabolic unhealthy 
profile (all p≤0.05) 






NMHO = 803 
NMUO = 594  
 
47.8 (6.3) - WC > 90 cm 
- HDL < 40 mg/dL 
- TG > 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose > 100 mg/ml 
MHO: none of the 
criteria met 
MUO: ≥ 1 of the 
criteria met  
 
- CRF (VO2peak in 
treadmill effort test, 
ml/kg·min) 
ANOVA No significant difference in CRF was 
observed between MHO and MUO 
(p>0.05) 






NMHO = 958 
NMUO = 435 
 
50.8 (5.7) - WC > 90 cm 
- HDL < 40 mg/dL 
- TG > 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose >100 mg/ml 
MHO: none of the 
criteria met 
MUO: ≥ 1 of the 
criteria met  
 
 
- CRF (VO2peak in 
treadmill effort test, 
ml/kg·min) 
ANOVA MHO showed higher CRF than MUO 
(p<0.001) 






NMHO = 22 
NMUO = 22 
 
57.6 (5.9) - Glucose disposal 
rates/FFM ≤ 9.29  
MHO: ≥ 12.62 
MUO: ≤ 9.29 
- CRF (VO2peak in 
ergocycle effort test, 
ml/kg·min) 
ANOVA No differences between MHO and 
MUO were found in CRF (p>0.05) 
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N = 45 
 
Subgroups: 
NMHO = 17 






- HDL < 40 mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 110 mg/dL 
MHO: none of the 
criteria met 
MUO: ≥ 1 of the 
criteria met 
- CRF (VO2max and 
1-min heart rate 
recovery in 
treadmill effort test 
or recumbent 
bicycle ergometer 
test, not specified) 






MHO presented better 1-min heart 
rate recovery after peak exercise 
performance compared with MUO 
(p=0.02) 
Messier et al, 
2008 
Montreal Ottawa New 
Emerging Team 







NMHO = 42 
NMUO = 42 
 
57.7 (4.8) - Hyperinsulinemic-
euglycemic clamp < 10.9 
MHO: belonging 
to tertile 3rd of HE 
clamp 
MUO: belonging 
to tertile 1st of HE 
clamp 











MHO had significantly higher 
VO2max compared with their MUO 
peers (p=0.028) 
 
Relative lower strength was not 
significant between MHO and MUO 
(p>0.05) 








NMHO = 26 






- HDL < 1.3 mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 5.6 mmol/L 
- HOMA > 5.13 
- hs-CRP > 0.1 mg/l 
 
Note: in the paper they 
provided results from 
different definitions (i.e. 
MHO: ≤ 1 of the 
criteria met 
MUO: ≥ 2 of the 
criteria met 
- CRF (VO2peak in 
graded exercise test 
on an ergocycle, 
ml/min·FFM) 
T-test Using the Clamp categorization, 
MHO presented higher VO2peak than 
those MUO (p<0.05). No significant 
differences were observed in terms of 
VO2peak between phenotypes and 
different categorizations applied 
58 
 
Clamp, Matsuda index, 
HOMA and Karelis). For 
more information see the 
paper 
 








NMHO = 1738 
NMUO = 3911 
44.2 (9.9) - HDL≤ 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥100 mg/dL 
 
Note: in the paper they 
provided results from 
obese categorized based 
on their BF%. For more 
information see the paper 
MHO: ≤ 1 of the 
criteria met  
MUO: ≥ 2 of the 
criteria met  











MHO participants had a better 
baseline fitness level than MUO 
participants, after adjustment for the 
set of confounders (p<0.001) 








NMHO = 10 
NMUO = 10 
 
51 (6) - WC ≥ 88 cm 
- HDL < 1.3 mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
 
MHO: none of the 
criteria met 
(excluding WC) 
MUO: ≥ 1 of the 
criteria met 
(excluding WC) 
- CRF (VO2max 
maximal exercise 
test on ergocycle, 
ml/kg·min) 
 
T-test MHO showed higher CRF than those 
MUO (p=0.04) 








NMHOO = 27 
NMUOO = 81 
 
15.2 (1.6) Age and gender- specific 
cut-off points by Jolliffe 
and Janssen (see article 
for more information) 
MHOO: none of 
the criteria met  
MUOO: ≥ 1 of the 
criteria met 





T-test CRF were not significantly different 
between MHOO and MUOO 
(p>0.05) 





41.7 (6.9) - WC ≥ 88 cm  
- HDL < 1.30 mmol/L 
- TG ≥ 1.7 mmol/L 
MHOO: none of 
the criteria met 
(excluding WC) 
-CRF (VO2max in 
maximum bicycle 
Not specified MHOO and MUOO did not differ in 







NMHOO = 42 
NMUOO = 36 
 
- SBP ≥ 130 mm Hg 
- DBP ≥ 85 mm Hg 
- Glucose ≥5.6 mmol/L 












NMHOO = 144 





61.1 (3.1) - WC ≥ 80 cm  
- HDL < 1.30 mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mm Hg 
- DBP ≥ 85 mm Hg 
- Glucose ≥6.1 mmol/L 
MHOO: ≤2 of the 
criteria met 
MUOO: ≥ 3 of 
the criteria met 






adjusted for age 
MHOO participants showed higher 
CRF than those with MUOO 
(p<0.001).  
Physical activity and sedentary behavior (N=55) 





N = 2833 
 
Subgroups: 
NMHOO = 332 
NMUOO = 580 
 
51.2 (14.7) - WC ≥ 88 cm 
- HDL < 50 mg/dl  
- TG ≥ 150 mg/dl  
- SBP ≥ 130 mmHg  
- DBP ≥ 85 mmHg 
- Glucose ≥ 100 mg/l 
MHOO: ≤ 1 of the 
criteria met 
(excluding WC) 




















MHOO participants showed higher 
light, moderate and vigorous PA than 
MUOO, but not statistically 
significant.  
In regards to energy expenditure, 
similar patterns were observed with 
the exception of the activity energy 
expenditure including housing hold 
activities for MHOO was 
significantly higher than for MUOO 
 




N = 3457 
 
69.2 (5.6) - HDL < 1.03♂ / 1.29♀ 
mmol/L  
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 5.6 mmol/L  
MHO: ≤ 1 of the 
criteria met 
MUO: ≥ 2 of the 
criteria met  
 
 












Higher total PA in MHO than in 
MUO is evident only when measured 
objectively. Likewise, associations of 
total PA with the different phenotypes 





NMHO = 580 
NMUO = 580 
 
- HOMA > 5.12   
  
no. participants 
above 2.5 h/week of 
MVPA)  
- Objective Total 
PA (GENEActiv 
accelerometer, mg 
and no. participants 







presence of an 
illness that 
limits MVPA 
Bell et al, 2014  English Longitudinal 
Study of Ageing 
Cross-sectional 
Random sample 
N = 4931 
 
Subgroups: 
NMHO = 299  
NMUO = 1135 
 
65.1 (8.9) - HDL < 1.03♂ / 1.29♀ 
mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- hs-CRP ≥ 3 mg/L 
- HbA1c ≥ 6%  
MHO: ≤ 1 of the 
criteria met 
MUO: ≥ 2 of the 





(how many hours 
during weekdays 
and weekend days, 
h) 
ANCOVA 
adjusted for age 






















Results of this study of older adults 
indicate that a common type of 
leisure-time sedentary behavior varies 
across metabolic and obesity 
phenotypes. However, the higher 
television viewing time observed in 
MHO was not significantly different 
with the observed in MUO 
 





N = 503 
45.8 (0.3) - WC > 94♂ / 80♀ cm 
- HDL < 1.03♂ / 1.29♀ 
mmol/L 
- TG ≥ 1.7 mmol/L 
MHOO: ≤ 2 of the 
criteria met 
 
- Reported physical 
training (no. 
sessions and time 
per session)  
ANOVA Frequency and duration of physical 
training were greater in MHOO than 





NMHOO = 44 
NMUOO = 459 
 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 5.6 mmol/L  









N = 86 
 
Subgroups: 
NMHOO = 18 
NMUOO = 68 
 
58.7 (1.3) - WC > 88 cm 
- HDL < 1.3 mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 6.1 mmol/L 
MHOO: ≤ 1 of the 
criteria met 
MUOO: ≥ 2 of the 
criteria met 
 
- Reported PA 
(Physical Activity 
Scale for the 
Elderly, z-score)  






Although MHOO presented higher 
mean PA level than MUOO, the 
difference was no significant 
Cadenas-Sanchez 








NMHOO = 190 
NMUOO = 47 
NMHO = 24 
NMUO = 8 
14.7 (1.3) Age and gender- specific 
cut-off points by Jolliffe 
and Janssen (see article 
for more information) 
MHOO: ≤1 of the 
criteria met 
(excluding WC) 






MHOO: none of 
the criteria met 
(excluding WC) 




Note: The same 
criteria were 
applied when the 
analyses were 
done for MHO 
and MUO 
 
- Objective SB 
(Accelerometry, 
min/day) 










MHOO showed lower time spent in 
SB and higher in MVPA compared to 
those peers MUOO (p<0.05). Overall, 
these results persisted when only 
obese adolescents were included in 
the analyses 
In sensitivity analyses, MHOO 
presented lower SB time (p=0.004) 
and borderline non-significant higher 
MVPA compared to MUOO 
(p=0.071). Taking into account only 
obese adolescents, no significant 




Camhi et al, 2015  Massachusetts (US) 
Cross-sectional 
Convenience sample 
N = 46 
 
Subgroups: 
NMHOO = 37 
NMUOO = 9 
26.7 (4.7) - HDL < 50 mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- HOMA > 5.49 
- hs-CRP > 14.4 mg/L 
 
 
MHOO: ≤ 2 of the 
criteria met  
MUOO: ≥ 3 of the 
criteria met  
 






- Reported SB and 













Compared to MUOO, MHOO young 
women demonstrate healthier lifestyle 
habits with less sedentary behavior 
and more time in light PA 




N = 766 
 
Subgroups: 
Adolescents (12-18 y) 
NMHOO = 163 
NMUOO = 62 
Young adults (19-44 y) 
NMHOO = 152 
NMUOO = 118 
Older adults (45-85 y) 
NMHOO = 64 














- HDL < 40 mg/dL 
- TG ≥ 110 mg/dL 
- SBP ≥ 90th percentile 
- DBP ≥ 90th percentile  
- Glucose > 100 mg/dL 
 
Young and older adults 
- HDL < 40♂ / 50♀mg/dL  
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose > 100 mg/dL 
 
MHOO: ≤ 1 of the 
criteria met  
MUOO: ≥ 2 of the 
criteria met  
 
- Reported PA 
(Interview, min/day, 
MET * min/day and 
no. training sessions 
and no. and time in 
active commuting) 
- Reported SB 
(Interview, no. 
participants 














Among adolescents, PA was not 
associated with MHOO. In contrast, 
MHOO adults 19–44 years were 85% 
more likely to engage in active 
transportation and 2.7 times more 
likely to be involved in light intensity 
usual daily activity versus sitting. For 
each minute per day, adults 45–85 
years were 36%more likely to have 
the MHOO phenotype with higher 
levels of moderate PA. SB was not 
associated with metabolic phenotypes 
in adolescents or adults 
Chang et al, 2016  Taiwan 
Cross-sectional 
Random sample 
N = 734 
 
Subgroups: 
NMHO = 91 
NMUO = 146 
56.5 (13.6) - WC > 90♂ / 80♀ cm 
- HDL < 1.04♂ / 1.3♀ 
mmol/L  
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 6.1 mmol/L  
- HOMA > 3.46 
 
MHO: ≤ 2 of the 
criteria met  
MUO: ≥ 3 of the 
criteria met  
 
 
- Regular exerciser 
(no. participants 
exercising more 
than once a week) 
Chi-squared  
T-test 
Compared with obese participants 
who had metabolic syndrome, those 
who were obese but did not have 
metabolic syndrome, were more 
likely to exercise regularly 
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De Rooij et al, 
2016 
The Maastricht Study 
Cross-sectional study 
Not specified 
N = 2449 
 
Subgroups: 
NMHO = 107 
NMUO = 440 
 
60.0 (8.1) - WC > 102♂ / 88♀ cm  
- HDL < 1.04♂ / 1.3♀ 
mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 6.1 mmol/L  
MHO: ≤ 2 of the 
criteria met  
MUO: ≥ 3 of the 
criteria met  
 
  




















After adjustments for age, sex, 
educational level, smoking, alcohol 
use, waking time, type 2 diabetes 
mellitus, history of cardiovascular 
disease and mobility limitation, MHO 
spent, per day, more time stepping 
(118.2 versus 105.2 min; p<0.01) and 
less time sedentary (563.5 versus 
593.0 min., p = 0.02) than MUO (n = 
440) 










NMHO = 335  
NMUO = 79  
 
19-44 years: 
NMHO = 691  
NMUO = 111  
 
45-85 years: 
NMHO = 1082  











Age and gender- specific 
cut-off points by Jolliffe 
and Janssen (see article 
for more information) 
 
19-44 / 45-85 years 
- HDL < 1 ♂ / 1.3♀ 
mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  





MHO: ≥ 1 of the 
criteria met 




MHO: none of the 
criteria met  
MUO: ≥ 1 of the 
criteria met  
 
45-85 years: 
MHO: none of the 
criteria met  
MUO: ≥ 1 of the 
criteria met  







MHO adults displayed a higher 1-
minute bout of MVPA per day 
compared to non-MHO (p = 0 02), 
but no difference was observed for 
MVPA and sedentary behavior 
patterns for youth and older adults. 
When adjusted for confounders, all 
bouts of sedentary behavior patterns 
in youth were significantly associated 
with being classified as MHO 
Ding et al, 2015  Beijing Child and 
Adolescent Metabolic 
Syndrome 
10.0 (1.9) - WC > 90th percentile for 
age and sex 
- HDL < 1.03 mmol/L  
- TG ≥ 1.24 mmol/L 
MHO: none of the 
criteria met  
MUO: ≥ 1 of the 
criteria met  




Chi-square  No significant differences were found 
between healthy and unhealthy 







N = 1149 
 
Subgroups: 
NMHO = 172  
NMUO = 297   
 
- SBP ≥ 90th percentile for 
age and sex 
- DBP ≥ 90th percentile for 
age and sex 




reporting at least 
exercise for once 
biweekly and over 
30 min per time) 
Donini et al, 2016  University of Rome 
Cross-sectional 
Convenience sample 
N = 253 
 
Subgroups: 
NMHO = 151 
NMUO = 102 
 
50.6 (11.9) - WC > 102♂ / 88♀ cm  
- HDL < 1.04♂ / 1.3♀ 
mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 6.1 mmol/L  
MHO: none of the 
criteria met  
MUO: ≥ 1 of the 
criteria met  
 






age, sex and 
BMI 
No physical activity differences 
between MHO and MUO was 
observed (p≥0.360) 
Doustmohamadian 
et al, 2017 
Tehran Lipid and 




N = 8804 
 
Subgroups: 
NMHOO = 1125  
NMUOO = 3686  
 
47.7 (12.6) - HDL < 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 100 mg/dL 
- 2-h blood glucose ≥ 140 
mg/dL 
 
MHOO: ≤ 1 of the 
criteria met  
MUOO: ≥ 2 of the 





(i.e. ≥ 89 cm for 










moderate or heavy 
lifestyle) 
Chi-Square  Between MHOO and MUOO, no 
significant differences were observed 
in PA 





N = 876 
 
11.9 (2.9) - HDL < 40 mg/dL 
- TG > 150 mg/dL 
- LDL > 130 mg/dL 
- Glucose ≥ 100 mg/dL 
- TC > 200 mg/Dl 
MHOO: none of 
the criteria met  
MUOO: ≥ 1 of the 
criteria met  
 
- Reported PA 
(frequency and 






A sedentary lifestyle was more 
common among MUOO children 
compared to the MHOO children 
(63.2% vs. 55.1%, respectively); and 




NMHOO = 363 
NMUOO = 513 
- HOMA > 2.5 
(prepubertal) > 4 
(pubertal) 
- TSH ≥ 0.34 
- Free thyroxine 4 ≥ 0.6 
- Hepatosteatosis (not 
defined the cut-off) 
- HTN (not defined the 
cut-off) 
 







lifestyle on metabolic health were 
found to be statistically significant 
(p = 0.048).  
 








NMHO = 10 
NMUO = 10 
 
46.4 (8.25) - WC > 102♂ / 88♀ cm 
- HDL < 1.03♂ / 1.30♀ 
mmol/L 
- TG ≥ 150 mg/dL 
- Glucose ≥ 5.6 mmol/L 
- HOMA > 4.27 
MHO: none of the 
criteria met 
MUO: ≥ 1 of the 
criteria met 




T-test There was no significant differences 
between MHO and MUO in physical 
activity levels (p=0.875) 
Goday et al, 2016 ICARIA study 
Spain 
Cross-sectional 




NMHO = 38600 
NMUO = 31452 
38.7 (10.6) - WC > 102♂ / 88♀ cm  
- HDL < 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mm Hg 
- DBP ≥ 85 mm Hg 
- Glucose ≥100 mg/dL  
MHO: ≤ 2 of the 
criteria met 













of exercise or no 
exercise) 
 
Chi-square In obese participants, those with a 
metabolically healthy phenotype 
showed higher levels of PA than 
those metabolically unhealthy 
(p<0.001) 
Gutiérrez-Repiso 
et al, 2014 




50.4 (0.2) - HDL < 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL 
- SPB ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
MHO: ≤ 1 of the 
criteria met  
MUO: ≥ 2 of the 
criteria met  







Moderate PA was associated with 




N = 5728 
 
Subgroups: 
NMHO = 338 
NMUO = 1089 
- Glucose ≥ 100 mg/dL  
- HOMA > 3.1 (90th 
percentile)  







once a week, 1-3 
times/week or >3 
times/week) 
Hankinson et al, 
2013  
The Internations 
Population Study on 
Macro/Micronutrients 
and Blood Pressure 
Cross-Sectional 
Random sample 
N = 775 
 
Subgroups: 
NMHO = 75 (men) 
NMHO = 74 (women) 
NMUO = 323 (men) 
NMUO = 303 (women) 
 
49.1 (5.2) - SPB ≥ 120 mmHg 
- DBP ≥ 80 mmHg  
- Presence of 
cardiovascular disease 
- Physician diagnosis, 
medication or special diet 
for diabetes or 
dyslipidemia 
MHO: none of the 
criteria met  
MUO: ≥ 1 of the 
criteria met  
 
 
- Reported PA (time 
sitting or doing light 
and MVPA, h/day) 
T-tests of 
means adjusted 
for age, race 
and education. 
Diet composition and most activity 
behaviors were similar between 
obesity phenotypes. These results do 
not support hypotheses that diet 
composition and/or physical activity 
account for the absence of 
cardiometabolic abnormalities in 
metabolically healthy obese 









NMHO = 1255 
NMUO = 536 
 
45.9 (8.9) - HDL < 1.03♂ / 1.29♀ 
mmol/L 
- TG ≥ 1.70 mmol/L 
- SBP ≥ 130 mm Hg 
- DBP ≥ 85 mm Hg 
- Glucose ≥5.6 mmol/L 
 
MHO: ≤ 1 of the 
criteria met 
MUO: ≥ 2 of the 
criteria met  
 
  
- Regular exerciser 
(no. participants 
exercising more 
than once a week) 
Chi-square No significant differences in the 
percentage of regular exercisers were 
observed between metabolic healthy 
and unhealthy phenotype (all p>0.05) 
Hayes et al, 2010  The Internations 
Population Study on 
Macro/Micronutrients 
and Blood Pressure 
Cross-Sectional 
Random sample 
N = 39 
46.8 (9.7) - HDL ≤ 1.1 mmol/L 
- TG ≥ 2.2 mmol/L 
- SBP ≥ 160 mmHg 
- DBP ≥ 95 mmHg 
- Glucose ≥ 6.1 mmol/L 
- 2-h blood glucose ≥ 7.8 
mmol/L 
MHO: none of the 
criteria met  




- Reported PA 
(Modifiable 
Activity 
Questionnaire, )  






A higher proportion of those with a 
healthy compared to a less healthy 
metabolic profile met current physical 
activity guidelines (70% vs 25%). 
Intra-abdominal fat, insulin resistance 
and physical activity make 





NMHO = 20  
NMUO = 19 
 
 metabolic status in very obese women 
but explain only around a third of the 
variance 






N = 223 
 
Subgroups: 
NMHOO = 40 (men) 
NMHOO = 70 (women) 
NMUOO = 48 (men) 
NMUOO = 65 (women) 
 
≥50 - TG ≥ 1.7 mmol/L 
- HDL ≤ 0.9♂ / 1.1♀ 
mmol/L  
- SBP ≥ 140 mmHg 
- DBP ≥ 90 mmHg 
- Glucose ≥ 6.1 mmol/L 
- 2-h blood glucose ≥ 7.8 
mmol/L 
 
MHOO: none of 
the criteria met  
MUOO: ≥ 1 of the 
criteria met  
 
 
- Reported PA 
(Medical Research 
Council’s National 
Survey of Health 
and Development, 
no. participants 
classified as low, 
medium or high PA) 
Logistic linear 
regression  
After adjusting for BMI, higher levels 
of physical activity were 
independently associated with being 
MHOO in men 




N = 223 
 
Subgroups:: 
NMHOO = 21 (men) 
NMHOO = 27 (women) 
NMUOO = 295 (men) 
NMUOO = 289 (women) 
15.1 (0.3) - HDL: diagnosed 
Hypoalphalipoproteinemia  
- TG ≥ 1.47 mmol/L 
- SBP ≥ 140 mmHg 
- DBP ≥ 90 mmHg 
- Glucose ≥ 7.0 mmol/L 
 
Note: in the paper they 
provided results from 
another different 
definition. For more 
information see the paper. 
MHOO: none of 
the criteria met  
MUOO: ≥ 1 of the 
criteria met  
- Reported PA 
(questionnaire on 
frequency and 











Physical activity and inflammation 
were not associated with MHOO in 







N = 6215 
 
47.4 (0.2) -WC > 89♂ / 91♀ cm 
- HDL < 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL  
- SBP ≥ 140 mmHg 
- DBP ≥ 85 mmHg 
- Glucose ≥ 100 mg/dL 
MHO: ≤ 1 of the 
criteria met 
(excluding WC) 
MUO: ≥ 2 of the 
criteria met 
(excluding WC) 
- Reported PA 
(Lipid research 
clinic questionnaire, 
no. participants who 
performed LPA, 
MPA or VPA) 
Chi-square 
 
Participants classified as MHO 
showed higher percentage of VPA 
and lower percentages in LPA than 




NMHO = 408  
NMHO = 1294 
 
 







NMHO = 309 
NMUO = 1781  
53.01 
(12.9) 
- WC > 90♂ / 80♀ cm  
- HDL < 40♂ / 50♀ mg/dL  
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg 




MHO: ≤ 1 of the 
criteria met 
MUO: ≥ 2 of the 
criteria met  
 
 




reporting 5 days of 
30 min/day of 
moderate PA or 3 
days with 20 
min/day of vigorous 
PA) 
 
Chi-square  MHO showed higher regular PA than 
MUO (p=0.038).  






NMHO = 1631 
NMUO = 336 
 
48.9 (7.4) - HDL < 1.036 mmol/L 
- TG > 1.695 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose > 6.1 mmol/L 
MHO: ≤1 of the 
criteria met 
MUO: ≥ 2 of the 










min/week of MVPA 





MHO showed higher PA compared to 
those with a metabolic unhealthy 
profile (all p≤0.05) 








NMHO = 40 
NMUO = 82 
 









Chi-square MHO participants did not show any 
significant difference in PA energy 
expenditure compare to MUO (all 
p>0.05) 





48.8 (0.6) - WC ≥ 102♂ / 88♀ cm 
- HDL < 1.04♂ / 1.29♀ 
mmol/L 
MHO: ≤ 2of the 
criteria met 
- Reported PA 
(questionnaire on 
frequency and 
Chi-square  MHO engaged in higher levels of 







NMHO = 816 
NMUO = 1937 
 
- TG ≥ 1.69 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 5.6 mmol/l 






active or active) 










NMHO = 269 
NMUO = 632 
59.1 (6.8) - WC ≥ 94♂ / 80♀ cm 
- HDL < 1.0♂ / 1.3♀ 
mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 5.6 mmol/l 
MHO: none of the 
criteria met 
MUO: ≥ 1 of the 
criteria met 









- Reported SB 






MHO exercised more regularly than 
MUO participants (p = 0.007) while 
no differences were found in 
sedentary behaviors (p ≥ 0.14) 
Kuzik et al, 2017 ICAD study 
Denmark, Estonia, 







NMHO = 394 
NMUO = 258 
 
11.8 (2.8) - HDL ≤ 1.17 mmol/L 
- TG ≥ 0.85 (age≤9) / 1.02 
(age>9) mmol/L 
- SBP ≥ 90th percentile  
- DBP ≥ 90th percentile 
- Glucose ≥5.56 mmol/L 
- HOMA ≥ 2.22♀ (age 
≤10), 2.67♂ (age ≤11), 
3.82♀ (age >10), and 
5.22♂ (age >11) 
MHO: none of the 
criteria met 






















In sedentary time, no significant 
differences were observed between 
groups (p>0.05) 
 
Each additional 10 min of MVPA was 
associated with lower odds of MUO 
compared with their metabolic 
healthy group (p≤0.05) 
Lassale et al, 2018 EPIC-CVD study 





- WC ≥ 94♂ / 80♀ cm  
- HDL < 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
MHO: ≤2 of the 
criteria met 
MUO: ≥ 3 of the 
criteria met 






center, sex, age, 
education, 
MUO were more moderately inactive 
than MHO (p=0.04). Likewise, MHO 








NMHO = 751 
NMUO = 909 
 
- DBP ≥ 85 mmHg  


















NMHO = 135 
NMUO = 610 
48.7 (7.5) - WC ≥ 90♂ / 80♀ cm 
- HDL < 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥100 mg/dL 
MHO: none of the 
criteria met 
MUO: ≥ 1 of the 
criteria met  
 
 




ANOVA No significant differences were 
observed between metabolic healthy 
phenotypes compared to those peers 
metabolically unhealthy (p=0.820) 







NMHOO = 451 
NMUOO = 247 
 
14.8 (2.0) - WC ≥ 90th percentile 
- HDL ≤ 40 mg/dL 
- TG ≥ 110 mg/dL 
- SBP ≥ 90th percentile 
- DBP ≥ 90th percentile 
- Glucose ≥100 mg/dL 
MHOO: none of 
the criteria met 
MUOO: ≥ 1 of the 
criteria met  
 
  
- Reported PA 
(questionnaire on 
frequency and 
duration, no. days 
per week of MVPA) 
ANOVA MHOO presented higher physical 
activity levels than MUOO (p=0.015) 
Matta et al, 2016 National Nutrition and 
Non-Communicable 




N = 196 
 
Subgroup: 
NMHOO = 73 
41.4 (14.7) - HDL ≤ 1.03♂ / 1.30♀ 
mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥5.6 mmol/L 
MHOO: ≥ 1 of the 
criteria met 
MUOO: ≥ 2 of the 
criteria met 
- Reported PA 
(IPAQ, no. 
participants 
classified as low, 




MHOO presented higher odds of high 




NMUOO = 123 
 
 







N = 45 
 
Subgroups: 
NMHO = 17 




- HDL < 40 mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 110 mg/dL 
MHO: none of the 
criteria met 
MUO: ≥ 1 of the 
criteria met 




There was no significant difference in 
meeting the PA guidelines between 
MHO and MUO (p=0.80) 








NMHO = 1262 




- HDL ≤ 1.03♂ / 1.30♀ 
mmol/L 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 100 mg/dL 
MHO: ≤ 1 of the 
criteria met 
MUO: ≥ 2 of the 
criteria met  
 
 





reporting at least 30 
min/day) 
Chi-square  MHO presented higher physical 
activity engagement than those peers 
with a metabolically unhealthy profile 
(all p<0.001) 










NMHO = 342442 
NMUO = 21439 









Chi-square  MHO showed higher PA levels than 












NMHO = 598 
NMUO = 1141 
 
44.9 (0.7) - HDL < 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 100 mg/Dl 
- HOMA > 90th percentile 
- hs-CRP > 90th percentile 
 
MHO: ≤ 1of the 
criteria met 
MUO: ≥ 2 of the 
criteria met 




meeting and not 
meeting  PA 
recommendations; 
and inactivity ) 
Chi-square  
 
Participants categorized as MHO did 
not show any significant difference in 
meeting or not meeting the PA 
recommendations and inactivity in 
comparison with those peers MUO 
(p=0.60). 
Phillips et al, 2013 The Cork and Kerry 








NMHO = 158 
NMUO = 512 
 
60.1 (0.3) - HDL < 1.04♂ / 1.30♀ 
mmol/L 
- TG ≥ 1.70 mmol/L 
- SBP ≥ 130 mm Hg 
- DBP ≥ 85 mm Hg 
- Glucose ≥ 5.55 mmol/L 
- HOMA > 90th percentile 
- CRP > 90th percentile 
MHO: ≤ 1 of the 
criteria met 




- Reported PA 
(IPAQ, no. 
participants 
classified as low, 
moderate, and high 
PA; meeting PA 
recommendations; 




MHO did not show any significant 
difference in the PA outcomes 
examined, including the total PA 
performed during the day compared 
to those peers MUO (all p>0.05) 








NMHO = 10 
NMUO = 10 
 
51 (6) - WC ≥ 88 cm 
- HDL < 1.3 mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
 
MHO: none of the 
criteria met 
(excluding WC) 
MUO: ≥ 1 of the 
criteria met 
(excluding WC) 




T-test Borderline non-significant between 
MHO and MUO in favor of a healthy 
phenotype was observed in the 
number of steps (p=0.06) 




12.9 (2.7) - HDL < 1.02♂ / 1.29♀ 
mmol/L 
- TG ≥ 1.25 mmol/L 
MHO: none of the 
criteria met  
MUO: ≥ 1 of the 
criteria met 




T-test MHO presented higher moderate PA, 
hard PA, and MVPA and lower 






NMHO = 39 
NMUO = 142 
 
- SBP ≥ 90th percentile for 
age, sex and height 
- DBP ≥ 90th percentile for 
age, sex and height 
-Glucose ≥ 5.6 mmol/L.  
 
Note: in the paper they 
provided results from 
another definition (i.e. 
HOMA). For more 
information see the paper. 
 
 
moderate, hard and 
very hard PA, 
min/day) 
- Objective PA 
(pedometer, 
steps/day) 




video game time 













NMHO = 83 
NMUO = 81 
 
37.7 (8.6) -WC ≥ 95 cm 
- HDL≤ 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥100 mg/dL 
 
MHO: ≤ 2 of the 
criteria met 
(including WC) 




- Reported PA 
(IPAQ, PA score) 
T-test No significant differences between 
MHO and MUO in the PA score 









NMHOO = 301 
NMUOO = 1144 
 
51.6 (11.8) - HDL≤ 40♂ / 50♀ mg/dL 
- TG ≥ 200 mg/dL 
- SBP ≥ 140 mmHg 
- DBP ≥ 90 mmHg  
- Glucose >125 mg/dL 
- TC ≥ 240 mg/dL 
- LDL ≥ 160 mg/dL  
MHOO: none of 
the criteria met 
MUOO: ≥ 1 of the 
criteria met 





T-test No significant difference were 
observed between MHOO and 
MAOO in leisure time PA (p=0.902) 






15.2 (1.6) Age and gender- specific 
cut-off points by Jolliffe 
and Janssen (see article 
for more information) 
MHOO: none of 
the criteria met  
MUOO: ≥ 1 of the 
criteria met 
- Objective PA 
(pedometer, 
steps/day) 
T-test PA were not significantly different 






NMHOO = 27 
NMUOO = 81 
 







NMHO = 1774 
NMUO-1 = 3479 
NMUO-2 = 4017 
 
48.6 (9.3) - HDL < 40 mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 100 mg/dL 
MHO: none of the 
criteria met 
(excluding WC) 
MUO-1: 1 of the 
criteria met 
(excluding WC) 
MUO-2: ≥ 2 of 
the criteria met 
(excluding WC) 
 




T-test MHO were more moderate-vigorous 
physically active than participants 
with MUO (p≤0.01) 









NMHO = 2925 
NMUO = 1341 
 
54.3 (6.5) - HDL < 50 mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 135 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 110 mg/dL 
MHO: ≤ 2 of the 
criteria met 
MUO: ≥ 3 of the 
criteria met  
 
 
- Reported PA 
(questionnaire, 
kcal/week) 
Not specified MHO presented higher PA than MUO 
(919 vs. 781 kcal/week, p value not 
given) 









40.2 (10) - SBP ≥ 140 mmHg 
- DBP ≥ 90 mmHg  
- Glucose ≥ 126 mg/Dl 
MHO: none of the 
criteria met 
MUO: ≥ 1 of the 
criteria met  
 
 
- Regular exerciser 
(no. participants 
exercising more 
than once a week) 
Chi-square  MHO showed higher levels of regular 





NMHO = 12731 





NMUO = 15906 
 














NMHOO = 7660 (non-
abdominal obese) 
NMHOO = 895 
(abdominal obese) 
 
NMUOO = 8060 (non-
abdominal obese) 
NMUOO = 3684 
(abdominal obese) 
 
42.8 (10.5) - WC ≥ 102♂ / 88♀ cm 
- HDL < 1.0♂ / 1.3♀ 
mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 5.6 mmol/L 
- TC ≥ 6.5 mmol/L 
 
Abdominal obese: 
MHOO: none of 
the criteria met 
(including WC) 






MHOO: none of 
the criteria met 
(excluding WC) 
MUOO: ≥ 1 of the 
criteria met 
(excluding WC) 












adjusted for age 
and sex 
MHOO with abdominal obesity was 
more physically active than those 
peers metabolically unhealthy (with 
abdominal obesity).  The same pattern 
is presented in those categorized as 
metabolically healthy and 
nonabdominal obese (all p<0.001) 








41.7 (6.9) - WC ≥ 88 cm  
- HDL < 1.30 mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mm Hg 
- DBP ≥ 85 mm Hg 
- Glucose ≥5.6 mmol/L 
MHOO: none of 
the criteria met 
(excluding WC) 





Not specified MHOO and MUOO did not differ in 




NMHOO = 42 
NMUOO = 36 
 





N = 5440 
 
Subgroups: 
NMHO = 528 
NMUO = 1137 
45.0 (0.4) - HDL < 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 100 mg/dL 
- HOMA >5.13 
- hs-CRP >0.1 mg/L 
MHO: ≤ 1 of the 
criteria met 
MUO: ≥ 2 of the 
criteria met  
 
 









Chi-square  No significant differences were found 
between MHO and MUO (all 
p>0.05). 
Yoon et al, 2017 Korea (Asia) 
Cross-sectional 
Random sample 
N = 530 
 
Subgroups: 
NMHO = 197 
NMUO = 333 
 
14.9 (0.2) - HDL < 40♂ / 50♀ mg/dL 
- TG ≥ 150 mg/dL 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
- Glucose ≥ 100 mg/dL 
MHO: none 
criteria met  
MUO: ≥ 1 of the 
criteria met 





PA and walking, 
min/day) 
Not specified  No significant differences were 
observed between MHO and MUO in 
PA (all p≥0.077) 






NMHOO = 144 
NMUOO = 40 
 
61.1 (3.1) - WC ≥ 80 cm  
- HDL < 1.30 mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mm Hg 
- DBP ≥ 85 mm Hg 
- Glucose ≥6.1 mmol/L 
MHOO: ≤2 of the 
criteria met 
MUOO: ≥ 3 of 
the criteria met 





adjusted for age 
No significant difference was found 
between groups in PA (p=0.364) 
Zhang et al, 2017 Liaoning (China) 
Cross-sectional 
Random sample 
N = 10804 
 
Subgroups: 
53.8 (10.3) - WC ≥ 90♂ / 80♀ cm 
- HDL < 1.0♂ / 1.3♀ 
mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg  
MHOO: none 
criteria met  









classified as light, 
Chi-square  Compared to MHOO participants, 




NMHOO = 112 
NMUOO = 4712 
 
- Glucose ≥ 5.6 mmol/L moderate and 
severe PA) 







NMHO = 470 
NMUO = 1567 
 
52.9 (10.0) - WC > 90♂ / 80♀ cm  
- HDL < 1.0♂ / 1.30♀ 
mmol/L 
- TG ≥ 1.7 mmol/L 
- SBP ≥ 130 mm Hg 
- DBP ≥ 85 mm Hg 
- Glucose ≥5.6 mmol/L 
MHO: ≤ 1 of the 
criteria met 
MUO: ≥ 2 of the 
criteria met 




moderate or high 
leisure PA) 
Chi-square MHO showed higher levels of PA 
compared to MUO peers (p<0.001) 
Zheng et al, 2015 Shanghai, Hangzhou, 
Beijing, Shenyang, 




N = 5013 
 
Subgroups: 
NMHO = 196 
NMUO = 506 
35-72 - HDL < 1.03♂ / 1.29♀ 
mmol/L 
- TG ≥ 1.7 mmol/L  
- SBP ≥ 130 mmHg 
- DBP ≥ 85 mmHg            
- Glucose ≥ 5.6 mmol/L 
MHO: ≤ 1 of the 
criteria met 
(excluding WC) 





- Reported PA 
(IPAQ, no. 
participants 
classified as short 
or moderate-high 
PA) 
 - Reported SB 
(IPAQ, no. 
participants 






gender, age and 
other factors 
Obese individuals with higher 
moderate  or long SB (p=0.039) and 
lower moderate or long PA (p=0.002) 
were significantly associated with 
metabolic abnormalities 
♂: males, ♀: females, WC: waist circumference, TG: triglycerides, HDL: high-density lipoprotein cholesterol, SBP: systolic blood pressure, DBP: diastolic blood pressure, HTN: hypertension, 
MHOO: metabolically healthy overweight/obese, MUOO: metabolically unhealthy overweight/obese, MHO: metabolically healthy obese, MUO: metabolically unhealthy obese, CRF: 
cardiorespiratory fitness, PA: physical activity,  LPA: light physical activity, MPA: moderate physical activity, VPA: vigorous physical activity, SB: sedentary, Cal: calories, PAEE: physical 
activity energy expenditure, HOMA: homeostatic model assessment, hs-CRP: high sensitivity c reactive protein, TSH: thyroid-stimulating hormone, MET: metabolic equivalent, TC: total 
cholesterol, VO2max: maximum oxygen consumption, VO2peak: peak oxygen consumption, BF%: body fat percentage, FFM: fat free mass, IPAQ: international physical activity questionnaire; 
ANCOVA: analysis of covariance, ANOVA: analysis of variance. 




-N sample include all participants in the study (not only those stated in the subgroups), thus, in some cases the first sample size provided in the setting-study design column is higher than the sum 
of those stated in the subgroups subsection.  
-When an article presented the data based on different metabolic phenotypes cut-offs, we have shown only that criterion that is closer to the last proposal provided by Ortega et al, 2017. 
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Aparicio et al, 2014  1 1 1 1 1 0 1 1 7 
Aparicio et al, 2016  1 1 0 1 1 0 1 1 6 
Bell et al, 2014  1 1 0 1 1 0 1 1 6 
Bell et al, 2015  1 1 1 1 1 1 1 1 8 
Berezina et al, 2015  1 1 0 1 0 0 1 1 5 
Bouchard et al, 2011  1 0 1 1 1 0 1 1 6 
Brochu et al, 2001  1 0 1 1 0 0 1 Unclear 4 
Cadenas-Sanchez et al, 
2017* 
1 1 1 1 1 1 1 1 8 
Camhi et al, 2013  1 1 0 1 1 0 1 1 6 
Camhi et al, 2015  1 1 1 1 1 0 1 1 7 
Carvalho et al, 2018  1 0 1 1 1 0 1 1 6 
Chang et al, 2016  1 1 0 1 1 0 1 1 6 
Dalzill et al, 2014 1 0 1 1 0 0 1 1 5 
De Rooij et al, 2016 1 1 1 1 1 0 1 1 7 
De Winter et al, 2018  1 1 1 1 1 0 1 1 7 
Ding et al, 2015  1 1 0 1 1 0 1 1 6 
Dobson et al, 2016  1 0 0 1 1 1 1 1 6 
Donini et al, 2016  1 1 1 1 1 0 0 1 6 
Doustmohamadian et al, 
2017 
1 1 1 1 1 0 1 1 7 
Elmaogullari et al, 2017 1 1 1 1 1 0 0 1 6 
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Gao et al, 2016  1 1 1 1 0 Unclear 0 1 5 
Goday et al, 2016 1 1 1 1 0 0 0 1 5 
Gregorio-Arenas et al, 
2016  
1 1 1 1 1 0 1 1 7 
Gutiérrez-Repiso et al, 
2014 
1 1 1 1 1 0 0 1 6 
Hankinson et al, 2013  1 1 1 1 1 0 0 1 6 
Hashimoto et al, 2017 1 1 1 1 1 1 0 1 7 
Hayes et al, 2006  1 1 1 1 1 0 0 1 6 
Hayes et al, 2010  0 0 1 1 1 0 0 1 4 
Heinzle et al, 2016  1 1 1 1 1 1 0 1 7 
Hosseinpanah et al, 
2011 
1 1 1 1 1 0 1 1 7 
Hwang et al, 2017 1 1 1 1 1 0 0 1 6 
Ingle et al, 2017* 0 0 0 1 1 1 1 1 5 
Jae et al, 2015 1 1 1 1 1 0 1 1 7 
Jae et al, 2017 1 1 1 1 1 0 1 1 7 
Jennings et al, 2008 1 0 1 1 1 0 0 1 5 
Kanagasabai et al, 2015 1 1 1 1 1 0 0 1 6 
Karelis et al, 2005 1 1 1 1 0 0 1 1 6 
Korhonen et al, 2015 1 1 1 1 0 0 0 1 5 
Kuzik et al, 2017 1 1 1 1 1 0 1 1 7 
Lassale et al, 2018 1 1 1 1 1 0 1 1 7 
Lee et al, 2013 1 1 1 1 1 0 0 1 6 
Lim et al, 2018 1 1 1 1 1 0 0 1 6 
Matta et al, 2016 1 1 1 1 1 1 0 1 7 
McElroy et al, 2016* 1 1 0 1 0 0 1 1 5 
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Messier et al, 2008 1 1 1 1 1 0 1 1 7 
Messier et al, 2010 1 1 1 1 0 0 1 1 6 
Moon et al, 2017 1 1 1 1 1 0 1 1 7 
Oh et al, 2014 1 1 1 1 1 0 0 1 6 
Ortega et al, 2013 1 1 1 1 1 0 1 1 7 
Park et al, 2016 1 1 1 1 1 0 0 1 6 
Phillips et al, 2013 1 1 1 1 1 0 0 1 6 
Poelkens et al, 2014* 0 0 1 1 0 0 1 1 4 
Prince et al, 2014 1 1 1 1 1 0 1 1 7 
Saghafi-Asl et al, 2017 1 1 1 1 0 0 0 1 5 
Schroder et al, 2014 1 1 1 1 1 0 0 1 6 
Senechal et al, 2013* 1 1 1 1 1 0 1 1 7 
Slagter et al, 2018 1 1 1 1 1 0 0 1 6 
Song et al, 2007 1 1 1 1 1 0 1 1 7 
Sung et al, 2015 1 1 1 1 1 0 1 1 7 
Van der A et al, 2014 1 1 1 1 1 0 1 1 7 
Wiklund et al, 2014* 1 1 1 1 1 1 1 1 8 
Wildman et al, 2008 1 1 1 1 1 0 0 1 6 
Yoon et al, 2017 1 1 1 1 1 0 0 1 6 
Yu et al, 2013* 1 1 0 1 1 0 1 1 6 
Zhang et al, 2017a 1 1 1 1 1 0 0 1 6 
Zhang et al, 2017b 1 1 1 1 1 0 0 1 6 
Zheng et al, 2015 1 1 1 1 1 0 0 1 6 




Table S5. Risk of bias of longitudinal studies included (N=11). 
 Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Item 7 Item 8 
Number of 
stars 
Appleton et al, 2013 A* A* C A* A*/ B* B* A* C 7 
Bo et al, 2012 A* A* C B A*/ B* B*  A* A* 7 
Doustmohamadian et al, 
2017 
A* A* C B A*/ B* B* A* B* 7 
Hosseinpanah et al, 2011 A* A* C B A*/ B* Unclear A* A* 6 
Lassale et al, 2017 A* A* C A* A*/ B* B* A* B* 8 
Loprinzi et al, 2017 A* A* C B A*/ B* B* A* A* 7 
Moon et al, 2017 A* A* C A* A*/ B* C A* D 6 
Ortega et al, 2013 A* A* A* A* A*/ B* B* A* C 8 
Song et al, 2007 A* A* C B A*/ B* B* A* A* 7 
Sung et al, 2015 A* A* C A* A*/ B* B* Unclear A* 7 
Van der A et al, 2014 A* A* C B A*/ B* B* A* A* 7 
The Newcastle Ottawa Scale for cohort studies can be found in Supplementary material 2. *Indicates that the study gets a star in the item examined.  
83 
 
A) Moderate-to-vigorous physical activity 
 
B) Sedentary behavior  
 
Figure S1. Funnel plots to assess publication bias on moderate-to-vigorous physical 
activity (Panel A) and sedentary behavior (Panel B) differences (pooled standardized 
mean difference) between metabolic phenotypes in overweight/obese participants.  
White point represents meta-analyzed observed studies whilst the black point shows the imputed studies. Diagonal 
lines represent pseudo-95% confidence intervals. In reference of Y axis, studies located at the lower part of the graph 
have a higher standard error (a lower weight in the pooled analysis). The vertical line represents the calculated 
standardized mean difference. 
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Funnel Plot of Standard Error by Std diff in means
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Figure S2. Forest plot of moderate-to-vigorous physical activity (Panel A) and sedentary 
behavior (Panel B) differences (pooled standardized mean difference) between 
metabolic phenotypes in obese participants.  
Standardized mean differences are expressed as MHO minus MUO, thus, positive values represents that MHO showed 
higher values than MUO. MHO: metabolically healthy obesity. MUO: Metabolically unhealthy obesity. CI: 








A) Moderate-to-vigorous physical activity 
 
B) Sedentary behavior  
 
Figure S3. Funnel plots to assess publication bias on moderate-to-vigorous physical 
activity (Panel A) and sedentary behavior (Panel B) differences (pooled standardized 
mean difference) between metabolic phenotypes in obese participants.  
White point represents meta-analyzed observed studies whilst the black point shows the imputed studies. Diagonal 
lines represent pseudo-95% confidence intervals. In reference of Y axis, studies located at the lower part of the graph 
have a higher standard error (a lower weight in the pooled analysis). The vertical line represents the calculated 
standardized mean difference. 
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A) Cardiorespiratory fitness 
 
B) Muscular strength 
 
Figure S4. Funnel plots to assess publication bias on cardiorespiratory fitness (Panel A) 
and muscular strength (Panel B) differences (pooled standardized mean differences) 
between metabolic phenotypes in overweight/obese participants.  
White point represents meta-analyzed observed studies whilst the black point shows the imputed studies. Diagonal 
lines represent pseudo-95% confidence intervals. In reference of Y axis, studies located at the lower part of the graph 
have a higher standard error (a lower weight in the pooled analysis). The vertical line represents the calculated 
standardized mean difference. 
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Funnel Plot of Standard Error by Std diff in means


















Std diff in means




Figure S5. Forest plot of cardiorespiratory fitness (Panel A) and relative muscular 
strength (Panel B) differences (pooled standardized mean difference) between metabolic 
phenotypes in obese participants.  
Standardized mean differences are expressed as MHO minus MUO, thus, positive values represents that MHO showed 
higher values than MUO. MHO: metabolically healthy obesity. MUO: Metabolically unhealthy obesity. CRF: 





A) Cardiorespiratory fitness 
 
B) Relative muscular strength 
 
Figure S6. Funnel plots to assess publication bias on cardiorespiratory fitness (Panel A) 
and relative muscular strength (Panel B) differences (pooled standardized mean 
difference) between metabolic phenotypes in obese participants.  
White point represents meta-analyzed observed studies whilst the black point shows the imputed studies. Diagonal 
lines represent pseudo-95% confidence intervals. In reference of Y axis, studies located at the lower part of the graph 
have a higher standard error (a lower weight in the pooled analysis). The vertical line represents the calculated 
standard differences in means. 
  



















Std diff in means
Funnel Plot of Standard Error by Std diff in means


















Std diff in means
Funnel Plot of Standard Error by Std diff in means
89 
 
A) All-cause mortality 
 
B) Non-fatal cardiovascular disease and cardiovascular disease mortality 
 
Figure S7. Funnel plot of metabolically healthy normal weight participants for the risk 
of all-cause mortality (Panel A) and non-fatal cardiovascular disease and cardiovascular 
disease mortality (Panel B) compared with metabolically healthy obese individuals after 
adjusting for physical activity.  
White point represents meta-analyzed observed studies whilst the black point shows the imputed studies. Diagonal 
lines represent pseudo-95% confidence intervals. In reference of Y axis, studies located at the lower part of the graph 
have a higher standard error (a lower weight in the pooled analysis). The vertical line represents the calculated hazard 
ratio. 




















Funnel Plot of Standard Error by Log hazard ratio























Figure S8. Forest plot of metabolically healthy normal weight participants for the risk of 
non-fatal cardiovascular disease and cardiovascular disease mortality compared with 
metabolically healthy obese individuals divided by 10 years of follow-up after adjusting 
for physical activity.  
Hazard ratio is presented having metabolic healthy normal weight phenotype as reference (1). MHO: metabolically 
healthy obesity. CI: confidence interval.  
